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Complications of Cushing’s syndrome: state of the art
Rosario Pivonello*, Andrea M Isidori*, Maria Cristina De Martino, John Newell-Price, Beverly M K Biller, Annamaria Colao
Cushing’s syndrome is a serious endocrine disease caused by chronic, autonomous, and excessive secretion of 
cortisol. The syndrome is associated with increased mortality and impaired quality of life because of the occurrence 
of comorbidities. These clinical complications include metabolic syndrome, consisting of systemic arterial 
hypertension, visceral obesity, impairment of glucose metabolism, and dyslipidaemia; musculoskeletal disorders, 
such as myopathy, osteoporosis, and skeletal fractures; neuropsychiatric disorders, such as impairment of cognitive 
function, depression, or mania; impairment of reproductive and sexual function; and dermatological manifestations, 
mainly represented by acne, hirsutism, and alopecia. Hypertension in patients with Cushing’s syndrome has a 
multifactorial pathogenesis and contributes to the increased risk for myocardial infarction, cardiac failure, or stroke, 
which are the most common causes of death; risks of these outcomes are exacerbated by a prothrombotic diathesis 
and hypokalaemia. Neuropsychiatric disorders can be responsible for suicide. Immune disorders are common; 
immunosuppression during active disease causes susceptibility to infections, possibly complicated by sepsis, an 
important cause of death, whereas immune rebound after disease remission can exacerbate underlying autoimmune 
diseases. Prompt treatment of cortisol excess and specifi c treatments of comorbidities are crucial to prevent serious 
clinical complications and reduce the mortality associated with Cushing’s syndrome.
Introduction
Cushing’s syndrome, or chronic endogenous hyper-
cortisolism, is a serious endocrine disease caused by 
chronic, autonomous, and excessive secretion of 
cortisol from the adrenal glands, with an estimated 
prevalence of around 40 cases per million and an 
estimated incidence of 0·7–2·4 cases per million per 
year, although the worldwide epidemiology has not 
been fully determined.1–3 Cushing’s syndrome is at least 
three times more prevalent in women than in men, and 
although it can occur at any age, is more frequent 
during the fourth to sixth decades of life.1–4 In the great 
majority of cases (around 70%), Cushing’s syndrome 
is caused by a pituitary tumour producing excessive 
adrenocorticotropic hormone (ACTH) that stimulates 
excessive cortisol secretion from the adrenal cortex, 
which is termed pituitary-dependent Cushing’s 
syndrome or Cushing’s disease. ACTH-independent 
adrenal production of cortisol by an adrenal tumour or 
bilateral adrenal hyperplasia or dysplasia is responsible 
for around 20% of cases of Cushing’s syndrome. 
An extrapituitary tumour secreting ACTH or, very 
rarely, corticotropin-releasing hormone, causes ectopic 
Cushing’s syndrome in the remaining roughly 10% of 
cases.1–4 Cushing’s syndrome can also be caused by 
excessive exposure to exogenous glucocorticoids, which 
is termed exogenous Cushing’s syndrome.1,2
In 1932, Harvey Cushing fi rst recognised a 
constellation of symptoms and signs in a group of 
patients, including obesity with adiposity localised on 
the face and trunk, wasting of the arm and leg 
musculature, with muscular weakness and fatigue, 
purplish striae on the abdomen, telangiectasias of the 
face, diff use ecchymoses, hypertension, hyperglycaemia, 
osteoporosis, depression, susceptibility to infections, 
menstrual irregularity in women, and decrease of libido 
in men.5 Most of these clinical manifestations are 
nowadays recognised as the main clinical features and 
complications associated with Cushing’s syndrome. 
The clinical picture of Cushing’s syndrome consists of 
weight gain with central obesity, fatigue with proximal 
myopathy, skin thinning with purplish striae, and 
easy bruising. Several comorbidities are associated 
with Cushing’s syndrome1,2,4 and are responsible for 
an impairment of quality of life and an increase 
in mortality.6
The diagnosis and determination of the origin 
of Cushing’s syndrome can be challenging and 
time-consuming, and requires diff erent laboratory 
tests and imaging procedures.7–9 Prompt and eff ective 
treatment is crucial for the reversal of comorbidities, 
prevention of serious acute and chronic complications, 
and protection from the increased mortality risk 
(panel 1).4,10,11 Notably, the increased mortality and 
morbidity that aff ect patients with Cushing’s syndrome 
during the active phase of the disease might not 
completely revert after disease remission (ie, resolution 
of hypercortisolism after an eff ective treatment). The 
reasons why surely morbidity and possibly mortality 
remain increased after remission of Cushing’s syndrome 
remain unclear. Beyond the irreversible damage of 
organs and systems induced by long-term cortisol 
excess, reasons that morbidity and mortality remain 
increased might include glucocorticoid withdrawal 
syndrome or adrenal insuffi  ciency, which can result from 
treatment for Cushing’s syndrome, or non-physiological 
adrenal replacement therapy in patients with adrenal 
insuffi  ciency after treatment for Cushing’s syndrome 
(panel 2).1,10–14
In this Review, we summarise key studies on mortality 
risk, and focus on the comorbidities and clinical 
complications of the diff erent types of endogenous 
Cushing’s syndrome. We present a detailed description 
of the pathophysiology of the comorbidities together 
with a systematic analysis of the studies on mortality 
and metabolic, skeletal, infectious, and autoimmune 
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complications associated with types of Cushing’s 
syndrome, during both active and remission phases of 
disease, where such information was available in the 
scientifi c literature. Finally, to aid clinicians who manage 
patients with active Cushing’s syndrome as well as those 
in remission, we discuss approaches that can be used in 
clinical practice for prevention of complications, such as 
antithrombotic and anti-infective prophylaxis. Notably, 
most reported studies on the clinical complications of 
Cushing’s syndrome do not represent high-quality 
evidence.
Mortality
Cushing’s syndrome is associated with excessive 
mortality, which is mainly caused by cardiovascular or 
infectious diseases, and their systemic consequences, 
mainly myocardial infarction, stroke, and sepsis.15 The 
excess mortality is usually seen in patients who do not 
achieve initial surgical remission, whereas in patients 
with postoperative hormonal control, mortality was 
described to be either increased or similar to that in the 
general population.15 In the past two decades, several 
studies have investigated the increased mortality from 
Cushing’s syndrome, primarily focusing on Cushing’s 
disease. 11 national or single-centre studies reported the 
standardised mortality ratio (SMR) of patients with 
Cushing’s syndrome,16–26 with variable fi ndings: 
six focused only on Cushing’s disease16,17,20–23 and fi ve also 
assessed patients with adrenal or ectopic Cushing’s 
syndrome.18,19,24–26 See appendix for a systematic analysis 
of the studies on mortality that reported the SMR in 
Cushing’s syndrome. In patients with Cushing’s disease, 
the overall SMR ranged from 0·98 to 9·3,16–26 being 
similar to17–20,25 or signifi cantly higher16,21–24,26 than the 
general population. There is consistent evidence that 
patients with persistent disease after pituitary surgery 
have the highest mortality. By contrast, data are 
discordant for patients with disease remission after 
treatment; several studies showed an SMR similar to that 
of the general population,19–21,25 but an increased SMR was 
reported in three diff erent UK studies and one New 
Zealand study.22–24,26
Cardiovascular disease is the major cause of death in 
patients with Cushing’s disease, either during active 
disease or after remission. Infectious diseases and sepsis 
represent frequent causes of death, and suicide 
associated with psychiatric disorders has also been 
described in patients with Cushing’s disease.6,15–26 The 
main predictive factors for mortality have been identifi ed 
as older age at diagnosis, the presence and duration of 
active disease, and the presence of comorbidities, mainly 
hypertension and diabetes.27,28 A recent meta-analysis on 
mortality in patients with Cushing’s syndrome, which 
included six studies that focused on patients with 
Cushing’s disease, confi rmed that Cushing’s disease is 
associated with increased mortality (SMR 1·84, 95% CI 
1·28–2·65), with highest mortality in patients with 
persistent or recurrent disease (3·73, 2·31–6·01). By 
contrast, mortality in patients with cured disease after 
initial pituitary surgery (SMR 1·23, 95% CI 0·51–2·97) 
does not signifi cantly diff er to that of the general 
population.29 This meta-analysis is in accordance with 
several available studies, suggesting that remission 
induced by surgery is crucial to protect patients with 
Cushing’s disease from premature death, although this 
concept is still debated and needs further studies to draw 
a defi nitive conclusion.
In patients with adrenal-dependent Cushing’s 
syndrome, including patients with benign adrenal 
pathology, the SMR varied substantially, from 1·35 to 
7·5,18,19,24–26 in adrenal adenomas, and from 1·14 to 12 in 
bilateral adrenal hyperplasia,18,24,25 being higher,18,24 
similar,19,25 or lower26 than that reported in patients with 
Cushing’s disease. The main causes of death were 
cardiovascular and cerebrovascular disease, thrombo-
embolism, infectious diseases or sepsis, and suicide. 
Patients with adrenal carcinoma, which carries a very 
poor prognosis, had a substantially increased SMR up to 
48·00 (95% CI 30·75–71·42), mainly because of 
neoplastic progression or pulmonary thrombo-
embolism.25,26
Panel 1: Specifi c treatments for the various types of Cushing’s syndrome1,2,10,11
• Management of adrenocorticotropic hormone (ACTH)-dependent Cushing’s 
syndrome requires a multidisciplinary and individualised approach. In general, the 
treatment of choice for ACTH-dependent Cushing’s syndrome is curative surgery with 
selective pituitary or ectopic corticotroph tumour resection, although this is not 
always possible or eff ective.
• In Cushing’s disease, second-line treatments include repeat pituitary surgery 
(generally with a more radical approach), pituitary radiotherapy, adrenal surgery 
(generally bilateral adrenalectomy), and pharmacological therapy.
• In ectopic Cushing’s syndrome, second-line treatments include radical surgery, 
radiotherapy, or chemotherapy, depending on the tumour responsible for the disease 
and the disease stage.
• ACTH-independent Cushing’s syndrome is usually treated by adrenal surgery, with the 
removal of the adrenal gland where the tumour is located, and less frequently with the 
removal of both glands, but rarely or transiently it can be treated with 
pharmacological therapy.
• In patients with a malignant adrenal tumour, extensive surgery and/or radiotherapy or 
chemotherapy might be necessary.
• Pharmacological therapy for Cushing’s syndrome consists of three categories of drugs:
• Adrenal-directed agents, which block cortisol production through inhibition of 
steroidogenesis enzymes—eg, ketoconazole and metyrapone (approved in the 
European Union for treatment of Cushing’s syndrome), and mitotane 
(generally off -label indication, apart from adrenal cancer);
• Pituitary-directed drugs, which act at the level of the pituitary tumour, inhibiting 
ACTH secretion, and which are useful for the treatment of Cushing’s disease—eg, 
pasireotide (approved worldwide for treatment of Cushing’s disease when surgery 
is not an option) and cabergoline (off -label indication);
• Glucocorticoid receptor-directed drugs which peripherally block the glucocorticoid 
receptor—eg, mifepristone (approved in the USA for patients with hyperglycaemia 
when surgery is not an option). 
See Online for appendix
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In patients with ectopic Cushing’s syndrome, SMR 
ranged from 13·3 to 68·5, as expected for the frequently 
malignant origin or aggressive behaviour of the 
disease.24–26 Beyond neoplastic progression, causes of 
death were typically infectious diseases or sepsis; one 
study noted skeletal complications as a cause of death.25
Morbidity
The excessive mortality associated with Cushing’s 
syndrome is a direct consequence of the multiple 
comorbidities aff ecting patients with this syndrome 
(fi gure 1). These comorbidities include a specifi c form of 
metabolic syndrome, characterised by hypertension, 
visceral obesity, impairment of glucose metabolism, 
and dyslipidaemia. This metabolic syndrome is 
strictly associated with cardiovascular disease, including 
vascular atherosclerosis and cardiac damage, which, 
together with thromboembolism and hypokalaemia, 
contribute to the increase in cardiovascular risk.1,2,4 
Additional clinical compli cations include musculoskeletal 
diseases, such as myopathy, osteoporosis, and skeletal 
fractures, as well as neuropsychiatric diseases, such 
as impairment of cognitive function, and psychiatric 
disorders, including mania or depression, which can 
result in suicide.1,2,4 An important complication of 
Cushing’s syndrome is the impairment of immune 
function, associated with severe infections or sepsis 
during active disease, which are a direct consequence of 
increased cortisol secretion. The decrease in cortisol 
during remission may result in immune rebound, which 
can induce a fl are of underlying autoimmune disorders. 
An impairment of reproductive and sexual function is 
frequently present in both men and women. In both 
sexes, dermatological manifestations are also common, 
but specifi c dermatological features (eg, acne, hirsutism, 
and alopecia) are typically associated with female sex.1,2,4 
Morbidity can be increased in the long term, being 
present before diagnosis and remaining in several 
patients even after many years of remission.28
Metabolic syndrome
Pathogenesis
Glucocorticoids regulate metabolism, and chronic 
hypercortisolism can lead to a specifi c form of the 
metabolic syndrome.28,30 Glucocorticoid excess aff ects a 
range of metabolic pathways determining the diff erent 
Panel 2: Adrenal insuffi  ciency and glucocorticoid withdrawal syndrome after resolution of hypercortisolism1,10–14
Successful treatment of Cushing’s syndrome might induce 
adrenal insuffi  ciency, which can last for several months to several 
years, because of suppression of the hypothalamic-pituitary-
adrenal (HPA) axis, but can be permanent if the HPA axis does 
not recover. After remission from Cushing’s syndrome, 
replacement therapy with glucocorticoids is used for adrenal 
insuffi  ciency. Hydrocortisone 10–20 mg/m² in two to three daily 
doses is the optimum current therapy, with half to two-thirds of 
the total dose taken in the morning; its short half-life might 
facilitate HPA axis recovery. Conversely, long-acting 
glucocorticoids should be avoided because they might prolong 
HPA axis suppression, and they have adverse metabolic 
consequences. Close monitoring of the HPA axis is needed, 
however, and morning serum cortisol concentrations before 
administration of glucocorticoids should be assessed 
approximately every 3 months for the fi rst 2 years. Three main 
outcomes are found: (1) a concentration of 500 nmol/L 
(18 μg/dL) or more means the HPA axis has recovered and 
glucocorticoids can be discontinued; (2) a concentration of less 
than 200 nmol/L mandates continuance of glucocorticoid 
therapy; and (3) concentrations ranging from 200 nmol/L 
(7 μg/dL) to 500 nmol/L are associated with incomplete HPA axis 
recovery; therefore, an adrenocorticotropic hormone stimulation 
test is recommended with stimulated serum cortisol 
concentrations of less than 500 nmol/L (18 μg/dL) identifying 
persisting adrenal insuffi  ciency, and higher concentrations 
allowing discontinuation of glucocorticoids.
In general, use of supraphysiological glucocorticoid doses is 
associated with increased morbidity and mortality, mainly from 
cardiovascular diseases. Therefore, adrenal insuffi  ciency 
replacement therapy should be tailored to each patient’s needs, 
avoiding over-treatment and under-treatment (which might 
make adrenal insuffi  ciency crises more likely). Another challenge 
is the need to replicate the physiological circadian rhythm of 
cortisol secretion. Standard hydrocortisone regimens result in 
supraphysiological circulating cortisol peaks, especially after 
afternoon and evening dosing, when concentrations of serum 
cortisol in healthy individuals are usually low. The inadequacies 
of current hydrocortisone regimens might have a role in the 
impaired glucose tolerance or diabetes, visceral obesity, 
hypertension, alterations of bone metabolism, and decreased 
quality of life seen in some patients with Cushing’s syndrome 
even after remission, and so contribute to residual mortality.
Patients in remission owing to Cushing’s syndrome treatment 
might also have glucocorticoid withdrawal syndrome, in which 
a rapid decrease in circulating cortisol concentrations after 
previous chronic overexposure is associated with lack of 
wellbeing and even a fl u-like syndrome, which might mimic 
adrenal insuffi  ciency, even in the presence of normal circulating 
cortisol concentrations. This disorder can be very challenging to 
manage. One strategy is to use pharmacological therapy to 
slightly reduce cortisol concentrations before defi nitive 
treatment for Cushing’s syndrome, whereas another more 
practical approach is to give glucocorticoids at higher than 
optimum replacement doses for several weeks after remission, 
but then to taper these as soon as possible, according to 
individual patient symptoms, so as to avoid inducing iatrogenic 
Cushing’s syndrome. 
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manifestations of this metabolic syndrome (fi gure 2). 
Glucocorticoids stimulate key enzymes involved in 
liver gluconeogenesis, increasing glucose output and 
circulating glucose concentrations,31,32 and cause hepatic 
and peripheral insulin resistance by direct and indirect 
mechanisms.31 Glucocorticoids also interfere with the 
insulin-stimulated translocation of glucose transporters 
(GLUT4) to the plasma membrane, thereby decreasing 
glucose uptake.32 In adipose tissue, glucocorticoids 
promote pre-adipocyte diff erentiation into adipocytes 
and decrease lipogenesis, also enhancing insulin-
induced lipogenesis.33 In adipose tissue and skeletal 
muscle, glucocorticoids reduce aminoacid uptake and 
increase lipid oxidation and lipolysis, whereas in the 
liver, glucocorticoids promote lipoprotein secretion and 
stimulate enzymes involved in fatty acid synthesis, 
contributing to the development of liver steatosis and 
impairing insulin sensitivity.31 These processes all 
contribute to glucocorticoid-induced insulin resistance, 
a major feature of the metabolic syndrome.30 In animal 
models, glucocorticoids inhibit pancreatic insulin 
secretion and in human beings they alter high-frequency 
insulin release in the fasting state.32 In line with these 
fi ndings, the alterations of glucose metabolism seen in 
patients with Cushing’s syndrome have been attributed 
to both glucocorticoid-induced insulin resistance 
and inadequate pancreatic β-cell com pensation.32 
Central eff ects of glucocorticoids on appetite have also 
been reported.34
Chronic hypercortisolism is mainly associated 
with abdominal obesity with preferential visceral fat 
accumulation.33 The mechanisms underlying typical 
fat distribution pattern are only partly understood. 
The enzyme 11β-hydroxysteroid dehydrogenase type 1 
(11β-HSD1) converts inactive cortisone to active cortisol, 
and diff erential 11β-HSD1 expression in tissues might 
aff ect local cortisol availability.33 11β-HSD1-knockout 
mice are protected from diet-induced obesity; 
conversely, animals overexpressing 11β-HSD1 have 
metabolic syndrome and visceral obesity.33 Therefore, 
diff erential expression of 11β-HSD1 in visceral versus 
subcutaneous adipose tissue might aff ect the fat 
distribution pattern, but data from human studies are 
scarce. Glucocorticoids exert their eff ects by binding 
glucocorticoid receptor types 1 and 2, and it has recently 
been suggested that varying expression of these 
receptors and their isoforms in diff erent tissues might 
infl uence the tissue-specifi c actions of glucocorticoids, 
contributing to the disparate eff ects observed in visceral 
and subcutaneous adipose tissue.33 The visceral adipose 
tissue in patients with Cushing’s syndrome has been 
reported to be structurally and functionally diff erent 
from that in people without Cushing’s syndrome; 
indeed, enlarged abdominal fat cells, increased 
lipoprotein lipase activity, and decreased lipolytic 
capacity were reported in female patients with 
Cushing’s syndrome compared with women without 
Cushing’s syndrome,33 whereas increased lipogenesis 
has been recorded in patients with Cushing’s syndrome 
compared with obese controls.35 The preferential 
accumulation of visceral fat in Cushing’s syndrome is 
associated with abnormal adipokine production, which 
might contribute to the development of metabolic 
syndrome.32 See appendix for a systematic analysis of 
studies on the metabolic syndrome in Cushing’s 
syndrome. 
Figure 1: Main comorbidities and clinical complications associated with mortality in patients with Cushing’s syndrome
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Visceral obesity
Weight excess, as documented by the pathological 
increase in BMI, is among the most common features of 
Cushing’s syndrome; indeed, weight excess is seen in 
57–100% of patients (overweight in 33–48% and obesity 
in 25–100%).23,36–43 However, the obesity associated with 
Cushing’s syndrome is abdominal rather than 
generalised weight gain, with preferential visceral rather 
than subcutaneous accumulation of fat tissue,36–40 as 
reported in studies using whole body magnetic 
resonance imaging.41 In a study of patients with pituitary 
or adrenal Cushing’s syndrome, waist circumference, a 
simple marker of visceral obesity, was signifi cantly 
higher in cases than in BMI-matched controls 
(p=0·0001), without signifi cant diff erences among types 
of Cushing’s syndrome.38 A pivotal role of visceral 
obesity in determining hypercortisolism-induced 
metabolic alter ations is substantiated by a correlation of 
waist-to-hip ratio, another marker of visceral obesity, 
with blood pressure, glucose concentration, and insulin 
concentration in patients with Cushing’s syndrome.36 
The duration of hypercortisolism correlates with the 
presence of obesity.37 Female patients with Cushing’s 
syndrome have a higher BMI than male patients,44 
although the prevalence of obesity is similar between 
men and women.45 Remission from hypercortisolism 
can improve, but does not consistently normalise weight 
excess, which can persist after short-term (1-year) or 
long-term (5-year) surgical remission.36,38,40 Two studies 
have reported an improvement in waist-to-hip ratio or 
waist circumference 1 year after surgical remission, 
particularly in patients with adrenal Cushing’s 
syndrome, although these parameters remained 
increased compared with controls.36,38
Pharmacological treatment can ameliorate excess 
weight in Cushing’s syndrome.46–55 In patients with 
various types of Cushing’s syndrome, 3 months’ 
treatment with ketoconazole reduced weight from 1 kg 
to 10 kg in about half of patients who were overweight 
or obese at baseline.49 Control of hypercortisolism after 
6 months’ treatment with mitotane signifi cantly 
reduced BMI (from median 28·3 [range 19·3–51·7] at 
baseline to 26·2 [16·3–46·3] after treatment; p<0·0001) 
in patients with Cushing’s disease,50 and treatment 
with mifepristone improved weight in patients 
with Cushing’s syndrome versus baseline.53 Among 
pituitary-directed drugs, pasireotide reduced weight 
(by –4·4 kg at 6 months, and –6·7 kg at 12 months), 
BMI (–1·6 kg/m² and –2·5 kg/m²), and waist 
circumference (–2·6 cm and –5·0 cm) even without 
complete biochemical control,55 whereas cabergoline 
improved waist-to-hip ratio after short-term treatment 
(1·10 at baseline vs 1·08 after 3 months) and reduced 
BMI after long-term treatment (28·2 kg/m² vs 
27·1 kg/m² after 24 months)46 in patients with Cushing’s 
disease versus baseline.
Impairment of glucose metabolism
An impairment of glucose metabolism has been 
described in 27–87% of patients with Cushing’s 
syndrome; in particular, impaired glucose tolerance is 
described in 7–64% of patients and diabetes in 11–47% 
of patients, whereas impaired fasting glucose has been 
less frequently investigated and reported in 6–14% of 
Figure 2: Main pathogenic mechanisms underlying the development of metabolic syndrome in patients with Cushing’s syndrome
Circled images represent the main organs that have a role in the metabolic abnormalities seen in patients with Cushing’s syndrome; the text below each organ 
describes the main mechanisms involved in the pathogenesis of these metabolic abnormalities and the main metabolic abnormalities determining metabolic 
syndrome in patients with Cushing’s syndrome. ↑ indicates increased; ↓ indicates decreased. GLUT4=glucose transporter type 4.
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patients.16,23,24,26–28,36–38,40–44,56 Glucose and insulin con-
centrations were higher in patients with Cushing’s 
disease compared with sex and age-matched controls 
and compared with BMI-matched controls after glucose 
loading,36 suggesting that some eff ects are independent 
of weight. The prevalence of impaired glucose tolerance 
or diabetes was higher in patients with pituitary or 
adrenal Cushing’s syndrome than in BMI-matched 
controls.38 No diff erence between the two disease types38 
or between sexes45 has been reported. However, the 
prevalence of diabetes in patients with ectopic Cushing’s 
syndrome (74%) is higher than in patients with other 
types of Cushing’s syndrome—eg, 33% in pituitary and 
34% in adrenal Cushing’s syndrome (both p<0·01).56 
Remission from hypercortisolism can improve, but 
does not always normalise glucose abnormalities.57 
5 years after surgical remission, the prevalence of an 
abnormality in glucose metabolism remained higher in 
patients with Cushing’s disease than in controls.40 In 
two studies, one exploring the eff ects of 1-year surgical 
remission in patients with pituitary and adrenal 
Cushing’s syndrome, and one exploring these eff ects in 
patients with pituitary Cushing’s syndrome only, 
glucose levels after an oral glucose tolerance test were 
slightly decreased compared with the active phase of 
disease and showed no signifi cant diff erence from 
controls.36,38 However, a signifi cant reduction in the 
prevalence of impaired glucose tolerance was noted 
only in patients with adrenal Cushing’s syndrome 
(7% 1 year after remission vs 40% at baseline, p=0·02),38 
suggesting that abnormal glucose metabolism might 
recover faster with treatment in this population than in 
patients with Cushing’s disease.
Generally, pharmacological treatment is associated 
with an improvement in glucose metabolism, with 
the exception of pasireotide. Adrenal-directed drugs 
positively aff ect glucose metabolism in patients with 
Cushing’s syndrome.47–50,58 Mifepristone improved insulin 
sensitivity and diabetes control in patients with 
Cushing’s syndrome.51–54 Among pituitary-directed drugs, 
cabergoline improved insulin sensitivity in the short 
term, and reduced the prevalence of impaired glucose 
tolerance or diabetes and reduced the requirement for 
antidiabetic medication during long-term treatment.46 By 
contrast, pasireotide worsened glycaemic control in 
patients with Cushing’s disease, particularly in those 
with pre-existing alterations of glucose metabolism.55,59 
Results from a study in healthy volunteers showed 
that pasireotide-induced hyperglycaemia is probably 
related to a direct inhibition of pancreatic insulin and 
gastrointestinal incretin secretion.60 Therefore, in 
patients on pasireotide treatment, glucose metabolism 
should be monitored and hyperglycaemia should be 
managed with metformin and a staged treatment 
intensifi cation with a dipeptidyl peptidase-4 inhibitor or a 
glucagon-like peptide-1 receptor agonist, or with insulin, 
as required, to achieve and maintain glycaemic control.61
Dyslipidaemia
Dyslipidaemia has not been extensively investigated, but 
it is described in 12–72% of patients with Cushing’s 
syndrome.23,24,27,36–38,42,44 Dyslipidaemia in Cushing’s syn-
drome is commonly characterised by raised total and 
LDL cholesterol and triglyceride concentrations, and 
reduced HDL cholesterol concentrations.24,36,37,44 An 
abnormal lipid profi le was noted in patients with pituitary 
and adrenal Cushing’s syndrome compared with 
controls,36,38 with similar fi ndings in patients with adrenal 
Cushing’s syndrome.38 Dyslipidaemia persisted 1 year 
after surgical remission in patients with pituitary or 
adrenal Cushing’s syndrome.36,38 A signifi cant decrease in 
concentrations of total cholesterol (5·6 mmol/L [SE 0·2] 
at baseline vs 4·3 mmol/L [0·2] after remission; p<0·004) 
and LDL cholesterol (3·5 mmol/L [0·2] vs 2·5 mmol/L 
[0·2]; p<0·004) was reported after remission in patients 
with adrenal Cushing’s syndrome, becoming similar to 
those in controls, without any signifi cant change in 
the otherwise reported normal HDL cholesterol or 
triglyceride concentrations; in this study, no changes 
were seen in patients with Cushing’s disease.38 However, 
in a study including patients with Cushing’s disease only, 
a signifi cant reduction in LDL cholesterol concentration 
(4·35 mmol/L [SE 0·6] at baseline vs 3·75 [0·5] after 
remission; p<0·05) was noted 1 year after surgical 
remission.36 After short-term (1-year) or long-term 
(5-year) remission, concentrations of total cholesterol 
and LDL cholesterol were higher than in sex-matched 
and age-matched, but not BMI-matched controls, 
suggesting that the persistence of obesity might 
contribute to the persistence of abnormal lipid profi le.36,40 
The eff ects of pharmacological treatment on the lipid 
profi le in Cushing’s syndrome are variable. Mitotane 
treatment increased concentrations of total cholesterol 
(median 5·8 mmol/L [range 3·5–8·2] at baseline vs 
7·7 mmol/L [5·1–14·0] under treatment; p<0·0001), LDL 
cholesterol (3·7 mmol/L [1·4–5·7] vs 4·2 mmol/L 
[1·9–10·9]; p<0·05), and HDL cholesterol (1·6 mmol/L 
[0·8–3·1] vs 1·8 mmol/L [1·0–3·6]; p<0·05), and 
triglycerides (1·2 mmol/L [0·4–11·8] vs 1·6 mmol/L 
[0·6–5·5]; p<0·01) in patients with Cushing’s disease.50 
Conversely, a reduction in total (0·6 mmol/L) and LDL 
cholesterol (0·5 mmol/L) concentrations after 12 months 
of treatment was reported in patients treated with 
pasireotide, and achieving a full control of cortisol 
secretion, although an improvement in lipid profi le was 
also found in patients uncontrolled under pasireotide.55
General considerations on metabolic syndrome
Transient or persistent adrenal insuffi  ciency was 
described in between 40% and 100% of patients with 
Cushing’s syndrome assessed for metabolic parameters 
after surgical remission.36,38,40 Since glucocorticoid replace-
ment treatment has been associated with an unfavourable 
metabolic profi le in patients with hypopituitarism,62 
glucocorticoid over-replacement after surgical remission 
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might have a role in the persistence of metabolic 
disorders in patients with Cushing’s syndrome. Diff erent 
post operative hormonal defi ciencies or their replacement 
might play a part in the abnormal metabolic profi le seen 
after remission from Cushing’s syndrome, especially 
Cushing’s disease. Taking into account the central role of 
insulin resistance in the pathogenesis of metabolic 
syndrome, the use of insulin sensitisers might be useful 
in patients with disorders of glucose metabolism in 
ameliorating the metabolic profi le during both the active 
and the remission phases of Cushing’s syndrome.63
Cardiovascular disease
Overview
Cardiovascular disease is commonly reported as the main 
cause of death in patients with Cushing’s syndrome. 
Indeed the increased mortality has traditionally been 
attributed to chronic damage from hypertension, in 
particular vascular atherosclerosis and cardiac remodelling 
and dysfunction.37,64,65 However, in the active phase, or in 
the early postoperative period, hypokalaemia and venous 
thromboembolism are also important contributors.66 
A range of changes in metabolic, haemodynamic, and 
coagulatory pathways induced by glucocorticoid excess are 
responsible for hypertension as well as vascular and 
cardiac disease, and thrombosis diathesis (fi gure 3).
Systemic arterial hypertension
Hypertension is a very common clinical feature of 
Cushing’s syndrome, occurring in 25–93% of 
patients.16,18,21–24,26–28,36–40,42,44,56,65,67–70 See appendix for a 
systematic analysis of the studies on hypertension in 
Cushing’s syndrome. Most studies showed that systolic 
and diastolic blood pressure was raised to a similar extent 
in these patients, with loss of the physiological nocturnal 
decrease being an early feature.64,71 Although the duration 
of uncontrolled hypercortisolism seems to correlate with 
development of hypertension in adults,64 half of paediatric 
patients with Cushing’s syndrome (whose time to 
diagnosis is shorter)72 still develop hypertension.64 The 
prevalence of hypertension is similar in male and female 
patients and among the various types of Cushing’s 
syndrome.37,45,56 The main mechanisms involved in the 
pathogenesis of hypertension in Cushing’s syndrome 
include the modifi cation induced by glucocorticoid 
excess in the renin-angiotensin system, the mineralo-
corticoid activity, the sympathetic nervous system, and 
the vasoregulatory system (panel 3). 
The ideal treatment of Cushing’s syndrome-related 
hypertension is the surgical removal of the tumour 
responsible for the disease. Remission from 
hypercortisolism can improve hypertension but it does 
not always normalise. In fact, the presence of hypertension 
has been reported in 25–54% of patients in remission 
from Cushing’s syndrome.36,38–40,65,67 Adrenal-directed 
drugs can worsen hypertension by increasing cortisol and 
aldosterone precursors with mineralocorticoid activity; 
these eff ects have been described for the 11β-hydroxylase 
inhibitors, metyrapone4 and osilodrostat (LCI699).73 
Mifepristone reduced blood pressure in about half of 
treated patients, although in some patients, hypertension 
and hypokalaemia worsened because of excessive cortisol 
concentrations, which saturate 11β-hydroxysteroid 
dehydrogenase type 2 (11β-HSD2), an enzyme that 
converts cortisol into cortisone, resulting in activation of 
mineralocorticoid receptors. This situation requires 
concurrent treatment with potassium and spirono-
lactone.74 Cabergoline and pasireotide improve 
hypertension, irrespective of any concomitant antihyper-
tensive drugs.46,55 However, pharmacological treatment 
for hypertension is often required (see appendix for 
fl ow-chart of proposed treatment of hypertension in 
Cushing’s syndrome).
Cardiac and vascular damage
Cushing’s syndrome is associated with an increased risk 
for myocardial infarction (hazard ratio [HR] 2·1, 95% CI 
0·5–8·6) and cardiac failure (6·0, 2·1–17·1).28 Concentric 
Figure 3: Main pathogenic mechanisms contributing to cardiovascular disease in Cushing’s syndrome
Figure shows the tissue abnormalities seen in aff ected organs, the main pathogenic mechanisms underlying 
cardiovascular disease in Cushing’s syndrome, and the consequent clinical complications. ↑ indicates increased; 
↓ indicates decreased. Hypertension, vascular remodelling, and atherosclerosis result from the interplay between 
several mechanisms regulating plasma volume, peripheral vascular resistance, and cardiac output, all of which are 
increased in Cushing’s syndrome. The mechanisms involved include the renin-angiotensin system, 
mineralocorticoid activity, the sympathetic nervous system, and the vasoregulatory system. Hypokalaemia 
increases the risk of malignant ventricular arrhythmias. The pro-infl ammatory status, altered angiogenesis, 
hyperinsulinaemia, and dyslipidaemia all contribute to increased intima-media thickness, development of 
concentric left-ventricular hypertrophy, impaired diastolic fi lling, and myocardial fi brosis. A remarkable rise in 
concentrations of factor VIII, von Willebrand factor, and platelets, and a shortening of the activated partial 
thromboplastin time, are frequently noted in Cushing’s syndrome. PAI-1=plasminogen activator inhibitor type 1.
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Myocardial fibrosis
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left ventricle hypertrophy, together with a decrease in 
systolic strain and impairment in diastolic fi lling caused 
by an abnormal relaxation pattern, has been described in 
Cushing’s syndrome.67,70,75 Patients with Cushing’s 
syndrome develop a more pronounced left ventricle 
hypertrophy than do hypertensive controls, suggesting 
that hypertension is not the only factor determining 
cardiac hypertrophy and consequent dysfunction.67 
Increased myocardial fi brosis—caused by an enhanced 
responsiveness to angiotensin II and activation of the 
mineralocorticoid receptor in direct response to cortisol 
excess—has been proposed as an underlying cause of the 
cardiac damage.76,77 Myocardial fi brosis could exacerbate 
the eff ects of hypokalaemia on QT interval prolongation 
seen in patients with Cushing’s syndrome;78 this eff ect is 
more evident in male than female patients, suggesting 
that the testosterone defi ciency observed in men with 
hypercortisolism could be a contributing factor.78
Vascular atherosclerosis is a common feature of 
Cushing’s syndrome. An increased prevalence of 
well-defi ned vascular wall plaques has been reported in 
patients with Cushing’s syndrome.36,42 The intima-media 
thickness of both carotid and aortic arteries can be 
increased in Cushing’s syndrome.36,42 A major role of 
insulin resistance in the development of vascular 
damage has been suggested, but diff erent factors such 
as glucocorticoid-induced endothelial dysfunction, 
enhancement of arterial stiff ness, thrombosis diathesis, 
increase in homocysteine, and decrease in taurine 
concentrations could also have a role.30,42,79 The vascular 
damage is probably the cause of the increased risk of 
stroke (HR 4·5, 95% CI 1·8–11·1) associated with 
Cushing’s syndrome.28 
The described cardiovascular changes are only partly 
reversible after successful treatment. Myocardial fi brosis 
and cardiac abnormalities showed a partial improvement 
after successful treatment of Cushing’s syndrome,80 
whereas vascular intima media thickness remained 
increased compared with controls for up to 5 years.36,40 In 
patients with active Cushing’s syndrome, intima media 
thickness was closely correlated to visceral adiposity and 
insulin resistance, suggesting a causative link; however, 
the loss of such correlation after remission suggests a 
role for additional factors such as persistence of 
hypertension or infl ammation.36,40,57
Cardiovascular morbidity was similar in glucocorticoid-
treated ACTH-insuffi  cient and ACTH-suffi  cient patients 
with hypopituitarism (stroke in 2·1% of patients and 
coronary heart disease in 4·3% of patients in both 
groups).62 However, whether glucocorticoid overexposure 
in patients with adrenal insuffi  ciency after disease 
remission contributes to the persistence of cardiovascular 
disease requires further investigation.
Thrombosis diathesis
Cushing’s syndrome is associated with a more than 
ten-fold increased risk of venous thromboembolism 
compared with people without Cushing’s syndrome.36,40,81,82 
Thromboembolic events have been reported in 6–20% of 
patients with Cushing’s syndrome, particularly in the early 
postoperative period.83 The increased cardiovascular 
mortality in Cushing’s syndrome, initially attributed 
predominantly to hypertension, is now also attributed to 
an increased thrombotic risk.66,81,82 Glucocorticoids are 
important physiological regulators of haemostasis and act 
on bone marrow, vessels, and liver.81 However, many 
studies have not discriminated between the eff ects of 
glucocorticoids per se, and the secondary eff ects of obesity 
and organ damage.66 Many alterations of coagulation and 
fi brinolysis occur in Cushing’s syndrome.66 A remarkable 
rise in factor VIII, fi brinogen, and von Willebrand 
factor levels, and a shortening of the activated partial 
thromboplastin time, are the hallmarks of the haemostatic 
alterations in Cushing’s syndrome, accompanied by a rise 
in the number of platelets, thromboxane B2, and 
thrombin–antithrombin complexes (table).66,82 Increased 
activity of endogenous coagulation inhibitors has also 
been reported, probably as a compensatory mechanism for 
the increased coagulatory factors. Impaired fi brinolytic 
capacity, which is refl ected by substantially increased levels 
of plasminogen activator inhibitor-1, has been described.66,82 
Haemo static abnormalities seem to improve 1 year after 
remission, although they do not fully normalise.81,82 In 
addition to an acute direct eff ect of glucocorticoids, a more 
sustained indirect eff ect mediated by chronic endothelial 
damage and atherosclerosis is probably involved.66
 Panel 3: Mechanisms involved in the pathogenesis of 
hypertension in Cushing’s syndrome64
Increased activity or concentrations
Renin-angiotensin system
• Angiotensinogen
• Pressor response to angiotensin II
• Angiotension II type 1A receptor
Mineralocorticoid activity
• 11β-hydroxysteroid dehydrogenase type 2 saturation
• Plasma volume
Sympathetic nervous system
• Sensitivity to β-receptor agonists
Vasoregulatory system
• Circulating endothelin 1
• Erythropoietin in patients treated for Cushing’s syndrome
• Circulating atrial natriuretic peptide
• Urinary kininase I, II, neutral endopeptidase
Decreased activity
Vasoregulatory system
• Atrial natriuretic peptide activity
• Nitric oxide pathway
• Urinary prostaglandin E2
• Prostacyclin I2 production
• Urinary kallikrein
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Successful pharmacological treatment does not seem to 
improve the hypercoagulable state, and this might be 
partly explained by persistence of the metabolic 
syndrome.66,82 In a retrospective analysis, postoperative 
antithrombotic prophylaxis reduced morbidity and 
mortality caused by thromboembolic events from 20% and 
10% to 6% and 0·4%, respectively.83 Routine antithrombotic 
prophylaxis has also been recommended during inferior 
petrosal sinus sampling, in addition to the immediate 
postoperative period after pituitary or adrenal surgery.6,66 
More intensive routine antithrombotic measures (adequate 
anticoagulant treatment and screening of haemostatic 
parameters) have been advocated for surgical prophylaxis 
in patients with Cushing’s syndrome.11,66 Since platelet 
activation has also been reported, a chronic anti-aggregation 
therapy could be considered.66
Hypokalaemia
Hypokalaemia aff ects more than half of patients with 
ectopic Cushing’s syndrome,69 but it can occur in any 
patient with severe Cushing’s syndrome. No diff erence 
was noted in the development of hypokalaemia in male 
and female patients with Cushing’s syndrome.45 Indeed, 
a signifi cant correlation was found between daily urinary 
cortisol excretion and severity of hypokalaemia.69 In 
Cushing’s syndrome, hypokalaemia causes a metabolic 
alkalosis that is not associated with chlorine depletion 
and is therefore unresponsive to saline administration. 
Hypokalaemia can be detected with the typical 
electrocardiogram signs, which include QT interval 
prolongation, and should be considered when starting 
pharmacological treatments aff ecting the QT interval. 
With worsening hypokalaemia, supraventricular tachy-
arrhythmias and life-threatening ventricular arrhythmias 
might occur. Hypokalaemia is often associated with 
hypomagnesaemia, which increases the risk of 
malignant ventricular arrhythmias.84 Hypo kalaemia has 
been attributed to excessive glucocorticoids saturating 
11β-HSD2, leading to inappropriate activation of the 
mineralocorticoid receptor.85 Worsening of hypokalaemia 
has been reported with adrenal-directed drugs that can 
increase cortisol precursors with mineralocorticoid 
activity, and also with mifepristone.74 Oral or parenteral 
correction of hypokalaemia and concomitant hypo-
magnesaemia is advocated.
Immunological disorders
Pathogenesis
Cushing’s syndrome is associated with immuno-
suppression during the active phase of the disease, 
which is responsible for the susceptibility to infections, 
and might be associated with an immune rebound after 
disease remission, which is responsible for the relatively 
frequent development or exacerbation of autoimmune 
diseases.57,86 Glucocorticoid excess induces substantial 
changes in the entire immune system (fi gure 4). 
Glucocorticoid excess interferes with host defence 
systems through hyperglycaemia and vascular damage, 
directly or indirectly.86 Glucocorticoids aff ect both the 
cellular and humoral components of the innate immune 
system. Indeed, glucocorticoids impair neutrophil 
function, eosinophil and monocyte production, 
macrophage maturation, and natural killer action, 
substantially altering the cellular response to infection.86 
Humoral components of the innate immune system are 
also infl uenced by glucocorticoids, aff ecting inhibition 
of lymphocyte proliferation and downregulation of 
relevant pro-infl am matory cytokines and complement 
com ponents.86 Moreover, gluco corticoids compromise 
aspects of the adaptive response through inhibition 
of antigen-presenting dendritic cells, aff ecting T-cell 
maturation, and limiting B-cell development and 
proliferation.86 Glucocorticoids infl uence the production 
and action of T-helper (Th) lymphocyte subclasses Th1 
and Th2, which are components of adaptive immunity; 
Th1 cells are the primary agents of cellular immunity, 
whereas Th2 cells are modulators of humoral immunity.86 
Th1 cells producing interferon γ, interleukin 2, and 
tumour necrosis factor β induce B cells to produce 
opsonising and complement-fi xing antibodies of the IgG 
class, whereas Th2 cells producing interleukins 4, 5, 6, 
10, and 13 induce B cells to produce immunoglobulins, 
particularly the IgE class. Gluco corticoids suppress Th1 
responses, with a consequent increase in susceptibility 
to intracellular and opportunistic infections, and 
promote Th2 responses, which could explain the 
possible development of certain autoimmune diseases 
 Coagulation phase 
during active phase
Coagulation phase 
during remission phase
Platelets
Platelet count = or ↑ NA
Thromboxane B2 ↑ NA
von Willebrand factor = or ↑ = or ↑
Coagulation cascade
aPTT = or ↓ = or ↓
Factor VIII = or ↑ = or ↑
Thrombin–antithrombin 
complexes
↑ NA
Fibrinogen = or ↑ ↑
Regulators of haemostasis
Protein C = or ↑ ↑
Protein S = or ↑ ↑
Antithrombin III ↑ =
Fibrinolysis
PAI-1 = or ↑ = or ↑
Table shows direction of association in reported studies, as reported in the 
scientifi c literature. ↑ indicates signifi cantly increased; ↓ indicates signifi cantly 
decreased; =indicates equal (compared with healthy controls). aPTT=activated 
partial thromboplastin time. NA=not applicable. PAI-1=plasminogen activator 
inhibitor type 1. 
Table: Haemostasis disorders in patients with Cushing’s syndrome 
during active and remission phases compared with controls66,81–83
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in patients with active Cushing’s syndrome.86,87 The Th1/
Th2 imbalance might also contribute to the uncontrolled 
immune response and rebound auto immunity during 
the remission phase of the disease. New-onset and 
exacerbations of autoimmune disease have been 
described after successful treatment of Cushing’s 
syndrome.57 The mechanism underlying the develop-
ment of autoimmunity in patients with Cushing’s 
syndrome after their cure has not been completely 
clarifi ed yet and requires further study. These fi ndings 
suggest that the eff ects of glucocorticoids on the 
immune system are far more complex than a universal 
immunosuppression.
Infectious diseases
The impairment of immune function associated with 
active Cushing’s syndrome predisposes patients to 
infectious diseases, especially opportunistic infections. 
See appendix for a systematic analysis of the studies on 
infectious diseases in Cushing’s syndrome. The high 
frequency of opportunistic infections in Cushing’s 
syndrome is linked to increased mortality; it is related to 
the time of exposure to hypercortisolism, and is associated 
with severe forms of Cushing’s syndrome.86 In a 
population-based cohort study, the prevalence of infections 
was increased in patients with Cushing’s syndrome before 
diagnosis (HR 2·4, 95% CI 1·0–5·9), similarly between 
pituitary and adrenal Cushing’s syndrome, being higher 
in the 1-year period before surgery (HR 5·7, 2·2–14·4) and 
peaking in the 3-month period after surgery (HR 38·2, 
95% CI 16·9–86·1), suggesting a cumulative eff ect of 
hypercortisolism exacerbated by surgery.28 A few studies 
primarily addressed the epidemiology of infections in 
Cushing’s syndrome, reporting a prevalence of 21–51%,88–
91 with a tendency towards a higher prevalence in ectopic 
Cushing’s syndrome (23–51%)88–90 than in Cushing’s 
disease (21%).91 The susceptibility to invasive infections 
seems to be independent of the type of Cushing’s 
syndrome, but is correlated with the severity of 
hypercortisolism.88,89,92 Because of the masking eff ect 
caused by the anti-infl ammatory action of glucocorticoids, 
total leucocyte counts or temperature are not reliable 
indicators of active infection, and the absolute 
concentration of cortisol is the best predictor of severe 
infection in patients with Cushing’s syndrome.89
The increased risk of infection associated with severe 
cortisol excess applies to virtually any microbial 
pathogen,86,93 but some infections are more common 
Figure 4: Main pathogenic mechanisms and clinical consequences of the immune disorders associated with Cushing’s syndrome
Glucocorticoid excess, together with hyperglycaemia and vascular damage, has detrimental eff ects on the innate and adaptive immune system. Main mechanisms 
underlying these immunological alterations range from various degrees of immune suppression exerted on lymphocytes, antigen-presenting dendritic cells, and 
natural killer cells, to a relative imbalance between Th1 and Th2 humoral immunity. The clinical consequences are an increased susceptibility to infections (ie, fungal, 
viral, and bacterial) during the active phase and rebound autoimmunity during the remission phase of Cushing’s syndrome. ↑ indicates increased; ↓ indicates 
decreased. Th=T-helper. IFNγ=interferon γ. IL=interleukin. TNFα=tumour necrosis factor α. TGFβ=transforming growth factor β. C3=complement component 3.
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than others. The most frequent infections are 
community-acquired and nosocomial bacterial 
infections86 caused by Gram-positive (Staphylococcus spp, 
Streptococcus spp, Listeria spp, and Nocardia spp) and 
Gram-negative (enterobacteria and Legionella spp) 
organisms.94 Fungal infections are also frequent, with 
the most typical fungal pathogens being Candida spp, 
Aspergillus spp, and Cryptococcus spp as well as 
Pneumocystis jirovecii.86,93 Invasive fungal infections 
should be suspected in patients with Cushing’s 
syndrome with early signs and symptoms of infection 
that are unresponsive to broad-spectrum antibiotics.95 
Conversely, when an opportunistic infection occurs in 
the presence of persistent severe hypokalaemia, 
Cushing’s syndrome should be considered, although the 
results of testing the hypothalamic-pituitary-adrenal axis 
during systemic illness can be diffi  cult to interpret.96 
Cushing’s syndrome is frequently associated with severe 
and persistent forms of common viral infections,86 
including herpes simplex, herpes zoster, and cyto-
megalovirus. Diff erent viruses, such as adenovirus, 
infl uenza virus, and Epstein-Barr virus, can also have 
more severe and protracted clinical courses in patients 
with Cushing’s syndrome than in people without 
Cushing’s syndrome.86 Control of hypercortisolism can 
often uncover an otherwise clinically silent opportunistic 
infection, due to the anti-infl ammatory eff ects of cortisol 
suppressing the signs and symptoms of infection.97 
Primary prophylaxis for Pneumocystis jirovecii infection 
with co-trimoxazole (or dapsone for patients with allergy 
to co-trimoxazole) has been proposed in all patients with 
very high concentrations of circulating cortisol.11,92 
Nevertheless, successful treatment of opportunistic 
infections often depends on the rapidity in normalising 
cortisol secretion.
Autoimmune diseases
A few studies have investigated the prevalence of 
autoimmune diseases in patients with Cushing’s 
syndrome, reporting a prevalence of a range of 
autoimmune disorders of 0–20% during the active phase 
and a higher prevalence of up to 60% during the 
remission phase of the disease.98–101 See appendix for a 
systematic analysis of the studies on autoimmune 
diseases in Cushing’s syndrome. Clinicians treating 
patients with Cushing’s syndrome need to be aware of 
this possible treatment outcome. The range of auto-
immune disorders is wide, with thyroid auto immunity 
the most commonly reported (prevalence 10–60%).100 
Coeliac disease can occur with a subtle presentation, or be 
associated weight loss; however, the weight loss observed 
in patients with coeliac disease can be wrongly attributed 
to the weight loss expected in patients in remission from 
hypercortisolism, thus obfuscating the diagnosis of 
coeliac disease. Testing patients with Cushing’s syndrome 
for autoimmune thyroiditis and coeliac disease is 
suggested, particularly during the 6 months after 
Cushing’s syndrome remission.100 Thymic hyperplasia 
might develop three or more weeks after remission from 
Cushing’s syndrome,102 but it may spontaneously regress. 
The diff erential diagnosis between thymic hyperplasia 
after control of hyper cortisolism and a thymic source of 
ectopic ACTH production can be challenging.
Musculoskeletal diseases
Skeletal damage
An impairment of bone status has been described 
in 64–100% of patients with Cushing’s syndrome; in 
particular, osteopenia occurs in 40–78%, osteoporosis in 
22–57%, and skeletal fractures in 11–76% of patients.24,56,103–114 
See appendix for a systematic analysis of the studies on 
skeletal diseases in Cushing’s syndrome. Bone mineral 
density (BMD) is reduced in patients with Cushing’s 
syndrome.103,104,106,108,110,113,115–118 An increased incidence of 
low-energy fractures occurs, particularly within the 
2–3 years before diagnosis and treatment,28,119 suggesting 
that prompt recognition and management of Cushing’s 
syndrome are essential to reduce skeletal complications. 
The prevalence of osteoporosis is higher in patients with 
adrenal Cushing’s syndrome than in those with pituitary 
Cushing’s syndrome.106,107 BMD appears to be lower and 
vertebral fractures more prevalent in ectopic than in 
pituitary Cushing’s syndrome.56,113 These data suggest that 
adrenal androgen suppression or disease severity could 
negatively aff ect bone status in Cushing’s syndrome, but 
this notion remains controversial, since some studies did 
not fi nd diff erences in bone disease frequency and severity 
in the diff erent types of Cushing’s syndrome.56,113,115,120 Male 
patients have a higher prevalence of osteoporosis 
(47% vs 32%, p<0·05;45 and 40% vs 20%, p<0·0556) and 
vertebral fractures (52% vs 18%; p<0·001)56 than female 
patients, suggesting that testosterone defi ciency could 
negatively aff ect bone status in Cushing’s syndrome. 
Amenorrhoeic and eumenorrhoeic women with 
Cushing’s syndrome have similar BMD values and 
fracture prevalence,108,113 suggesting that the harmful 
eff ects of glucocorticoids overcome oestrogenic bone 
protection in Cushing’s syndrome.
Glucocorticoid excess aff ects bone status through a 
number of diff erent mechanisms (fi gure 5). Gluco-
corticoids exert their eff ects on bone metabolism directly 
through uncoupling bone turnover, and indirectly through 
alteration of calcium homoeostasis and impairment of 
pituitary hormone secretion. Catabolic eff ects on muscles 
might also have a role, since these eff ects lead to muscle 
weakness and disuse, diminishing the muscle trophic 
eff ect on bone.121–123 Glucocorticoids induce an imbalance 
between bone formation and bone reabsorption; they 
inhibit osteoblast diff erentiation and function, promote 
osteoblast and osteocyte apoptosis via the activation of 
caspase 3, and prolong osteoclast lifespan. Inhibition of 
osteoblast diff erentiation has been attributed to inactivation 
of the Wnt/β-catenin signalling pathway and induction of 
nuclear factors of the CCAAT-enhancer-binding protein 
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family and peroxisome proliferator-activated receptor γ 
type 2, whereas blockade of type I collagen synthesis by 
diff erentiated osteoblasts has been shown to reduce the 
bone matrix available for mineralisation.121 The decreased 
number of osteocytes induces bone microarchitectural 
alterations, reducing bone surface turnover in response to 
mechanical forces.121 Glucocorticoids also increase the 
receptor activator of nuclear factor kappa-B ligand and 
decrease osteoprotegerin production in osteoblasts, 
promoting increased osteoclastic activity.121,123 Finally, 
diff erential sensitivity of bone cells to glucocorticoid action 
has been described: patients with the N363S polymorphism 
in glucocorticoid receptors121,123 and higher 11β-HSD1 
activity121 could have a higher likelihood of glucocorticoid-
induced bone damage.
Surgical remission improved BMD in most 
studies.24,104,105,111,112,118,120 In patients with adrenal Cushing’s 
syndrome, an improvement in BMD at the lumbar spine 
but not at the femoral neck was noted 3 months after 
hypercortisolism remission.105 In a mixed population 
including patients with pituitary and adrenal Cushing’s 
syndrome, BMD improved in both lumbar spine and 
femoral neck, but only after follow-up longer than 
6 months.111 Several prospective studies assessing bone 
status in patients followed up for at least 1 year after 
remission from hypercortisolism reported a progressive 
improvement in BMD,104,105,111,112,118,120 generally more slowly 
in the femoral neck than the lumbar spine.105,118,120 In a 
group of patients with Cushing’s disease, lumbar spine 
BMD was still lower than in controls 2 years after 
remission,104 whereas lumbar spine and femoral neck 
BMD normalised in patients with Cushing’s syndrome 
after a mean follow-up of 71 months.118 These data 
highlight the potential reversibility of bone damage with 
control of hypercortisolism, although the time to complete 
bone recovery is relatively long and variable. A greater 
increase in BMD after remission has been reported in 
male than female patients.120 Notably, the duration of 
glucocorticoid replacement was negatively correlated with 
lumbar spine BMD in women with Cushing’s syndrome 
in long-term surgical remission,115 suggesting that several 
factors, including sex and glucocorticoid over-replacement 
might aff ect the time to bone recovery.
Few data regarding the eff ects of pharmacological 
treatment on bone disease are available. Despite the 
lowering of cortisol, no signifi cant improvement in BMD 
Figure 5: Main pathogenic mechanisms underlying the alteration of skeletal structure and function in Cushing’s syndrome
The main pathogenic mechanisms directly related to bone are included in the main box. Circled images represent the main cell types or bone components that have a 
role in the alteration of skeletal structure and function in patients with Cushing’s syndrome. The main pathogenic mechanisms indirectly related to bone are 
represented outside the main box. Ca²+=calcium. CCAAT-EBP=enhancer-binding protein family. IGF-1=insulin-like growth factor 1. mTOR=mechanistic target of 
rapamycin. PPARγ2=peroxisome proliferator-activated receptor γ type 2. RANKL=the receptor activator of nuclear factor kappa-B ligand.
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was recorded in two small cohorts of patients with 
Cushing’s disease treated with ketoconazole for up to 
100 months,116,124 whereas amelioration was reported in 
three patients treated for more than 36 months.47 A better 
outcome after 6 months has been reported in patients 
with Cushing’s syndrome treated with ketoconazole plus 
alendronate.116 Recommendations for the treatment of 
osteoporosis induced by exogenous hypercortisolism can 
be only partly translated to patients with endogenous 
Cushing’s syndrome; therefore, specifi c guidelines for 
these patients are still needed. Stratifi cation of patients 
into two treatment subgroups—according to the cause of 
Cushing’s syndrome, gonadal status, age, presence of 
fractures, and expected time for hypercortisolism 
resolution—has recently been suggested.125 These sub-
groups are patients with less severe bone damage, needing 
only supplementation with calcium and vitamin D 
(eg, those not presenting with prevalent fractures, 
pre menopausal women, and men younger than 50 years), 
and patients with more severe bone damage requiring 
more aggressive treatment such as bone active therapy 
with bisphosphonates, teriparatide, and denosumab 
(eg, those with severe hypercortisolism, prevalent hip or 
vertebral fractures, and those older than 70 years).125 
Although active bone therapy might be eff ective in 
endogenous Cushing’s syndrome, further investigation is 
needed to make specifi c treatment recommendations.
Muscle damage
Myopathy has been frequently described in patients with 
Cushing’s syndrome, with a prevalence ranging from 
42% to 83%.1,24,45,56 Cushing’s syndrome myopathy more 
severely aff ects the proximal part of lower limbs,126 and 
can take months to years to resolve. The prevalence of 
myopathy is slightly higher in ectopic than in adrenal 
Cushing’s syndrome56 and signifi cantly higher in male 
than female patients.45
Glucocorticoid excess aff ects the structure and function 
of skeletal muscle through diff erent mechanisms 
(fi gure 5). Glucocorticoids induce type 2 muscle fi bre 
atrophy through both anti-anabolic and catabolic 
actions.126,127 Glucocorticoids impair protein synthesis in 
muscle by inhibiting aminoacid uptake, repressing the 
insulin-like growth factor 1 (IGF-1)-activated mechanistic 
target of rapamycin pathway, and inhibiting myogenesis 
by downregulating myogenin.127 Glucocorticoids also 
stimulate proteolysis particularly through the ubiquitin–
proteosome system.127 The alteration of local growth 
factors such as the inhibition of IGF-1, the stimulation of 
myostatin, and the impairment in mitochondrial 
function and sarcolemmal excitability also contribute to 
glucocorticoid-induced myopathy.126,127
Musculoskeletal pain and acute bilateral carpal tunnel 
syndrome have been described as a result of cortisol 
withdrawal syndrome after surgical remission.128 The 
reversibility of myopathy after surgical or pharmacological 
remission of Cushing’s syndrome, and the role of 
preventive interventions such as the use of anabolic 
factors or physical activity programmes, need further 
investigation.126
Neuropsychiatric diseases
Neuropsychiatric diseases are severe comorbidities of 
Cushing’s syndrome, in both the active and remission 
phases;6,129,130 this topic is reviewed in detail in a recent 
review of the scientifi c literature.129 The most common 
psychiatric diseases in Cushing’s syndrome are major 
depression (prevalence 50–81%), anxiety (66%), and 
bipolar disorders (30%).129 Chronic brain exposure to 
cortisol excess causes deep structural and functional 
changes in various cerebral areas that are rich in 
glucocorticoid receptors, particularly the hippocampus, 
amygdala, and prefrontal cortex, including the limbic 
system, all of which are fundamental regions for 
emotional and cognitive functions.131–133
Some studies have reported an improvement in 
neuropsychiatric disorders after disease remission 
obtained by either surgery or pharmacological treatment, 
but resolution of hypercortisolism is not always followed 
by complete recovery, suggesting irreversible adverse 
eff ects on the central nervous system.129 The persistence or, 
rarely, the worsening of depression or anxiety after disease 
remission might also depend on adrenal insuffi  ciency 
and frequent overexposure to glucocorticoid replacement 
therapy.134 Besides normalisation of cortisol secretion, 
psychotherapeutic strategies, such as cognitive behavioural 
therapies and psychotropic drugs, including antidepressant 
agents (eg, tricyclic agents and selective serotonin reuptake 
inhibitors), can be useful in treating psychiatric disorders 
associated with Cushing’s syndrome.130 Benzodiazepines 
can help in cases of severe anxiety.130 These data highlight 
the importance of long-term follow-up and careful periodic 
investigation of neuropsychiatric complications associated 
with Cushing’s syndrome.129
Reproductive and sexual disorders
General considerations
Reproductive and sexual disorders in Cushing’s syndrome 
are very common.1,2,4 Decreased libido (24–90%), hypo-
gonadism in men (50–75%), and menstrual irregularity in 
women (43–80%) are the most common clinical features, 
the latter more frequent in patients with pituitary than in 
those with adrenal Cushing’s syndrome.2,24,37,56,135–138 Fertility 
is seriously impaired in patients with Cushing’s syndrome, 
but this might also be a consequence of the reduced libido 
and lower frequency of sexual activity. Reports that women 
with Cushing’s syndrome often do not seek pregnancy 
because of their serious clinical conditions suggest that 
the physical eff ects of the syndrome on reproduction are 
under estimated.139 In Cushing’s syndrome, the hypo-
thalamic-pituitary-gonadal axis can be aff ected at diff erent 
levels. The alteration of the hypothalamus-pituitary-
gonadal axis, together with several metabolic alterations, 
are responsible for the impairment of fertility and 
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sexuality associated with Cushing’s syndrome (fi gure 6). 
Chronic hypercortisolism can block gonadotropin-
releasing hormone and gonadotropin release.139,140 Visceral 
adiposity and liver steatosis are associated with 
abnormalities in sex steroid metabolism, reduction in sex 
hormone-binding globulin, and androgen excess.56,135,136 
Intermediate steroids with weak androgenic activity are 
produced within adipose tissue and can disrupt 
hypothalamic–pituitary feedback.7,141 Glucocorticoids can 
also directly infl uence the gonads through a glucocorticoid 
receptor-mediated inhibition of sex steroid hormone 
production and cell apoptosis.
Ovarian damage
In women, clinical symptoms and signs of Cushing’s 
syndrome can resemble those of polycystic ovary 
syndrome (PCOS), including hirsutism, acne, oligo-
amenorrhoea, insulin resistance, and obesity.135,136,141 
Therefore, the diff erential diagnosis between mild 
Cushing’s syndrome and PCOS is often diffi  cult, and 
women with proven Cushing’s syndrome might initially 
be diagnosed with isolated PCOS.142 PCOS can be 
associated with an abnormal hypothalamic-pituitary-
adrenal  axis with increased urinary cortisol and 
midnight serum cortisol concen trations compared with 
obese individuals.135,136,141,143 Testosterone concentrations 
were also tested in the diff erential diagnosis between 
mild Cushing’s syndrome and PCOS; symptomatic 
women with a total testosterone of less than 1·39 nmol/L 
were more likely to need a work-up for Cushing’s 
syndrome.144 However, the yield of testing can be low; in 
a study of 950 women with clinical hyperandrogenism, 
72% had PCOS and none were diagnosed with Cushing’s 
syndrome.145 PCOS and Cushing’s syndrome frequently 
coexist,135 but the ovaries in Cushing’s syndrome have 
distinct pathological features including a reduction in 
primordial follicles, an absence of cortical stromal 
hyperplasia and luteinisation, and the presence of 
fi brosis and volumetric decrease, consistent with 
reduced gonadotropin stimulation.146 It is also necessary 
Figure 6: Main pathogenic mechanisms underlying reproductive and sexual disorders in Cushing’s syndrome
Circled images represent the main organs that have a role in the sexual abnormalities seen in patients with Cushing’s syndrome. From the top (in the middle), 
hypercortisolism can block the release of gonadotropin-releasing hormone (GnRH) from the hypothalamus and luteinising hormone (LH)/follicle-stimulating 
hormone (FSH) from the pituitary gland leading to hypogonadotropic hypogonadism. In Cushing’s disease, adrenocorticotropic hormone (ACTH) provides an 
additive block on the release of gonadotropins from the pituitary. Additionally, circulating sex hormone concentrations are altered as a result of changes in 
sex-steroid binding proteins (sex hormone-binding globulin [SHBG] and albumin) and increased liver metabolism. At gonadal levels, the testis (left side of fi gure) 
shows disorganised seminal epithelium, maturation arrest, advanced tubular atrophy, and Leydig cell impairment, leading to oligospermia. The appearance of ovaries 
(right side of fi gure) varies from a polycystic appearance to a volumetric reduction caused by hypogonadotropic hypogonadism. The histological fi ndings include 
reduced primordial follicles, absence of cortical stromal hyperplasia, and fi brosis. Clinical presentation includes decreased libido and erectile dysfunction in men, and 
oligomenorrhoea or amenorrhoea and hirsutism in women. PCOS=polycystic ovary syndrome.
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to rule out adrenal carcinoma in patients with very high 
testosterone concentrations.147
Treatment with metyrapone or osilodrostat in women 
increases androgen concentrations further, and might 
worsen acne and hirsutism.4,73 Hormone replacement 
therapy during the active phase of Cushing’s syndrome 
is not usually recommended in women, because of the 
high thromboembolic risk, but it should be considered 
after successful treatment if gonadal function has not 
been restored.8 The abnormalities of gonadal status 
improve after disease remission and are also reversible, 
with successful pregnancies reported after remission of 
Cushing’s syndrome.148
Despite its rarity, pregnancy during active Cushing’s 
syndrome can be problematic because of severe maternal 
and fetal complications. The most common maternal 
complications are hypertension (68%), impairment 
of glucose metabolism (25%), pre-eclampsia (14%), 
osteoporosis and skeletal fractures (5%), psychiatric 
disorders (4%), cardiac failure (3%), wound infections 
(2%), and maternal death (2%).149 The most frequent 
fetal morbidity is prematurity, which occurs in about 
43% of pregnancies. Additional complications include 
intra uterine growth retardation (21%), stillbirths (6%), 
spontaneous abortion or intrauterine death (5%), and 
adrenal insuffi  ciency (2%).149 More than 150 cases of 
pregnancy in Cushing’s syndrome have been reported, 
most frequently in patients with adrenal tumours 
(60%).150 No pharmacological therapies are approved in 
pregnancy and some are contraindicated; prompt 
surgical treatment is the fi rst-line approach, although 
there are anecdotal reports of successful pharmacological 
treatment, mostly with the use of metyrapone.149
Testicular damage
In men, clinical symptoms and signs of Cushing’s 
syndrome can include features of hypogonadotropic 
hypogonadism, including erectile dysfunction.56 
Oligospermia is common and has been associated with 
histopathological fi ndings of the testis, including 
disorganised seminal epithelium, sloughing of immature 
elements, tubular thickening, and fi brosis. Maturation 
arrest, advanced tubular atrophy, and a decreased number 
of Leydig cells were recorded only in severe, untreated, or 
fatal cases of Cushing’s syndrome.137 Plasma testosterone 
and gonadotropin were found to be substantially decreased 
during active disease, but testosterone concentrations 
spontaneously normalised after remission, and remained 
at these normal concentrations during long-term 
follow-up.138,151 Although reversibility of hypogonadism is 
frequent, for patients without normal testosterone 
concentrations within 3 months after treatment, 
testosterone replacement is suggested to protect bone 
status.8 No data are available on semen quality after 
treatment for Cushing’s syndrome. Treatment with 
ketoconazole in men has been associated with 
gynaecomastia, hypogonadism, and erectile dys function.152
Dermatological manifestations
Dermatological manifestations are common in Cushing’s 
syndrome, with a prevalence of about 60–90%, and 
include skin and hair abnormalities.1,45,56,153,154 Skin 
abnormalities include the typically purple striae, together 
with facial plethora, bruising, disturbed healing, 
hyperhidrosis, hyperpigmentation, acanthosis nigricans, 
and acne, whereas hair abnormalities include hirsutism 
and alopecia.1,153,154 The prevalence of skin abnormalities 
has been reported to be higher in ectopic than in adrenal 
Cushing’s syndrome.56 Wide purple striae are more 
frequent in male than female patients, whereas no 
sex-related diff erences have been recorded in the 
prevalence of acne and ecchymoses.45
Glucocorticoids impair keratinocytes and dermal 
fi broblast proliferation as well as synthesis and turnover 
of collagen and mucopolysaccharides, leading to skin 
atrophy and vascular fragility. These eff ects are associated 
with thinned dermis and epidermis, retarded wound 
healing, and increased tendency to form purple striae, 
petechiae, and ecchymoses. Adrenal androgens are the 
main cause of hirsutism, acne, and alopecia, but increased 
protein catabolism has also been associated with follicular 
damage and alopecia. Facial plethora is generally 
attributed to polycythaemia and is commonly associated 
with facial telangiectasias.153 Increased concentrations 
of ACTH, which bind to melanocortin receptors on 
melanocytes, cause cutaneous hyperpigmentation in 
patients with ACTH-dependent Cushing’s syndrome.152 
Acanthosis nigricans can be caused by hyperinsulinism 
and refl ects insulin resistance, which together with 
dyslipidaemia contributes to the development of acne.154 
Skin abnormalities substantially improve and pro-
gressively disappear after surgical or pharmacological 
remission of hyper cortisolism, apart from purple striae, 
which typically become lighter, but often persist for life 
and require specifi c dermatological treatment.153,154
Search strategy and selection criteria
We searched PubMed for papers published in English during the past 30 years (between 
Jan 1, 1986, and August 1, 2015) using the following MESH search terms: 
“hypercortisolism” OR “Cushing’s disease” OR “Cushing’s” OR “Cushing” OR “ectopic 
Cushing’s syndrome” OR “endogenous hypercortisolism” OR “glucocorticoids” and any of 
the following: “mortality”; “death”; “morbidity”; “complication”; “metabolism”; “metabolic 
syndrome”; “obesity, glucose tolerance”; “diabetes mellitus”; “dyslipidaemia”; 
“hypercholesterolaemia”; “hypertriglyceridaemia”; “cardiovascular”; “hypertension”; 
“coagulopathy”; “venous thromboembolism”; “thrombosis”; “electrolytes”; “infections”; 
“fungal infections, viral infections, bacterial infections”; “sepsis”; “immunodepression”; 
“immunosuppression”; “immune system”; “thyroiditis”; “celiac disease”; “LES”; “lupus”; 
“Graves’ disease”; “immune disease”; “autoimmune”; “autoimmunity”; “bone diseases, 
osteopenia, osteoporosis, fractures”; “cognitive function”; “psychiatric disease”; 
“depression”; “mania”; “fertility”; “infertility”; “ovary”; “testis”; “PCOS”; “hypogonadism”; 
“semen”; “spermatogenesis”; “erectile dysfunction”; “sexual function”. We gave particular 
emphasis to original molecular studies, prospective observational data, controlled trials, 
and larger registry data .
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Conclusions
Cushing’s syndrome is associated with many 
comorbidities and increased mortality, but with eff ective 
treatment most patients normalise cortisol secretion, with 
consequent improvement in clinical picture including 
comorbidities and mortality risk. The duration of disease 
activity is correlated with the mortality risk and negatively 
aff ects comorbidities; therefore, prompt diagnosis and 
treatment of Cushing’s syndrome is crucial. Treatment 
specifi c to the various comorbidities should be provided in 
parallel with therapy targeting cortisol excess to accelerate 
their resolution or improvement, and reduction of 
mortality risk. Comorbidities can persist in a subgroup of 
patients even after remission, necessitating continuing 
management, but the persistence of an increased 
mortality risk remains debated. Many questions remain 
about the clinical complications associated with Cushing’s 
syndrome. There is a need for studies with high-quality 
data regarding comorbidities to guide future evidence-
based clinical care. Large population studies that better 
characterise comorbidities in Cushing’s syndrome will 
be useful to identify the best possible treatments. 
Understanding the reasons for the variability in clinical 
improvement among diff erent patients will also be 
important, and prospective studies that compare the 
eff ects of surgical versus pharmacological treatment on 
comorbidities associated with Cushing’s syndrome will be 
helpful for the treatment decision process. Moreover, 
studies should explore whether the persistence of 
comorbidities in patients who are in remission might at 
least partly relate to overexposure to glucocorticoids 
from replacement therapy with supraphysiological 
glucocorticoid con centrations. In addition to providing 
better management for patients with Cushing’s syndrome, 
fi ndings of these studies might also provide insight 
into the clinical complications induced by exogenous 
glucocorticoid therapy, which is commonly used for many 
disorders worldwide.
Contributors
RP, AMI, JN-P, BMKB, and AC made substantial contributions to 
conception and design of the manuscript. RP, AMI, and MCDM were 
involved in acquisition of data, analysis and interpretation of literature, 
and elaboration and drafting of the manuscript, fi gures, and tables. JN-P, 
BMKB, and AC made substantial contributions in revising the content 
as well as the style and the English wording of the manuscript. All 
authors read and approved the fi nal manuscript.
Declaration of interests
RP reports grants, personal fees, and other from Novartis; grants and 
personal fees from Pfi zer; grants from HRA Pharma; grants and personal 
fees from ViroPharma-Shire; personal fees from Italfarmaco; personal 
fees from Ipsen; and personal fees from Ferring, outside the submitted 
work. AMI reports personal fees from Menarini, personal fees from 
Otsuka, grants and personal fees from Viropharma-Shire, and personal 
fees from Novartis, outside the submitted work. JN-P reports grants and 
personal fees from HRA Pharma, grants and personal fees from 
Novartis, and grants and personal fees from Ipsen, outside the submitted 
work. BMKB reports grants and personal fees from Cortendo, grants 
and personal fees from Novartis, personal fees from HRA Pharma, and 
personal fees from Ipsen, outside the submitted work. AC reports grants, 
personal fees, and other from Novartis; grants and personal fees from 
Pfi zer; grants from HRA Pharma; grants and personal fees from 
Italfarmaco; grants, personal fees, and other from Ipsen; and grants 
from Ferring, Lilly, and Novo Nordisk, outside the submitted work. 
MCDM declares no competing interests.
Acknowledgments
We thank Chiara Simeoli, Claudia Pivonello, Renata Simona Auriemma, 
Rosario Ferrigno, Donatella Paola Provvisiero, Roberta Patalano, 
Carlotta Pozza, Laura Rizza, Vincenzo Giannetta, and Marianna Minnetti 
for their contribution to this manuscript. This manuscript has not been 
supported by any specifi c grant from any funding agency in the public, 
commercial, or not-for-profi t sector.
References
1 Pivonello R, De Martino MC, De Leo M, Lombardi G, Colao A. 
Cushing’s syndrome. Endocrinol Metab Clin North Am 2008; 
37: 135–49, ix.
2 Newell-Price J, Bertagna X, Grossman AB, Nieman LK. 
Cushing’s syndrome. Lancet 2006; 367: 1605–17.
3 Steff ensen C, Bak AM, Rubeck KZ, Jørgensen JO. Epidemiology of 
Cushing’s syndrome. Neuroendocrinology 2010; 92 (suppl 1): 1–5.
4 Pivonello R, De Leo M, Cozzolino A, Colao A. The treatment of 
Cushing’s disease. Endocr Rev 2015; 36: 385–486.
5 Cushing H. The basophil adenomas of the pituitary body and their 
clinical manifestations. Bull Johns Hopkins Hosp 1932; 50: 137–95.
6 Feelders RA, Pulgar SJ, Kempel A, Pereira AM. The burden of 
Cushing’s disease: clinical and health-related quality of life aspects. 
Eur J Endocrinol 2012; 167: 311–26.
7 Newell-Price J, Trainer P, Besser M, Grossman A. The diagnosis 
and diff erential diagnosis of Cushing’s syndrome and 
pseudo-Cushing’s states. Endocr Rev 1998; 19: 647–72.
8 Arnaldi G, Angeli A, Atkinson AB, et al. Diagnosis and 
complications of Cushing’s syndrome: a consensus statement. 
J Clin Endocrinol Metab 2003; 88: 5593–602.
9 Nieman LK, Biller BM, Findling JW, et al. The diagnosis of 
Cushing’s syndrome: an Endocrine Society Clinical Practice 
Guideline. J Clin Endocrinol Metab 2008; 93: 1526–40.
10 Biller BM, Grossman AB, Stewart PM, et al. Treatment of 
adrenocorticotropin-dependent Cushing’s syndrome: a consensus 
statement. J Clin Endocrinol Metab 2008; 93: 2454–62.
11 Nieman LK, Biller BM, Findling JW, et al, and the Endocrine Society. 
Treatment of Cushing’s syndrome: an Endocrine Society clinical 
practice guideline. J Clin Endocrinol Metab 2015; 100: 2807–31.
12 Crowley RK, Argese N, Tomlinson JW, Stewart PM. Central 
hypoadrenalism. J Clin Endocrinol Metab 2014; 99: 4027–36.
13 Hochberg Z, Pacak K, Chrousos GP. Endocrine withdrawal 
syndromes. Endocr Rev 2003; 24: 523–38.
14 Grossman A, Johannsson G, Quinkler M, Zelissen P. Therapy of 
endocrine disease: perspectives on the management of adrenal 
insuffi  ciency: clinical insights from across Europe. Eur J Endocrinol 
2013; 169: R165–75.
15 Clayton RN. Mortality in Cushing’s disease. Neuroendocrinology 
2010; 92 (suppl 1): 71–76.
16 Etxabe J, Vazquez JA. Morbidity and mortality in Cushing’s disease: 
an epidemiological approach. Clin Endocrinol (Oxf) 1994; 40: 479–84.
17 Swearingen B, Biller BM, Barker FG 2nd, et al. Long-term mortality 
after transsphenoidal surgery for Cushing disease. Ann Intern Med 
1999; 130: 821–24.
18 Pikkarainen L, Sane T, Reunanen A. The survival and well-being of 
patients treated for Cushing’s syndrome. J Intern Med 1999; 
245: 463–68.
19 Lindholm J, Juul S, Jørgensen JO, et al. Incidence and late 
prognosis of Cushing’s syndrome: a population-based study. 
J Clin Endocrinol Metab 2001; 86: 117–23.
20 Hammer GD, Tyrrell JB, Lamborn KR, et al. Transsphenoidal 
microsurgery for Cushing’s disease: initial outcome and long-term 
results. J Clin Endocrinol Metab 2004; 89: 6348–57.
21 Dekkers OM, Biermasz NR, Pereira AM, et al. Mortality in patients 
treated for Cushing’s disease is increased, compared with patients 
treated for nonfunctioning pituitary macroadenoma. 
J Clin Endocrinol Metab 2007; 92: 976–81.
22 Clayton RN, Raskauskiene D, Reulen RC, Jones PW. Mortality and 
morbidity in Cushing’s disease over 50 years in Stoke-on-Trent, UK: 
audit and meta-analysis of literature. J Clin Endocrinol Metab 2011; 
96: 632–42.
www.thelancet.com/diabetes-endocrinology   Published online May 10, 2016   http://dx.doi.org/10.1016/S2213-8587(16)00086-3 17
Review
23 Hassan-Smith ZK, Sherlock M, Reulen RC, et al. Outcome of 
Cushing’s disease following transsphenoidal surgery in a single 
center over 20 years. J Clin Endocrinol Metab 2012; 97: 1194–201.
24 Bolland MJ, Holdaway IM, Berkeley JE, et al. Mortality and 
morbidity in Cushing’s syndrome in New Zealand. 
Clin Endocrinol (Oxf) 2011; 75: 436–42.
25 Yaneva M, Kalinov K, Zacharieva S. Mortality in Cushing’s 
syndrome: data from 386 patients from a single tertiary referral 
center. Eur J Endocrinol 2013; 169: 621–27.
26 Ntali G, Asimakopoulou A, Siamatras T, et al. Mortality in 
Cushing’s syndrome: systematic analysis of a large series with 
prolonged follow-up. Eur J Endocrinol 2013; 169: 715–23.
27 Lambert JK, Goldberg L, Fayngold S, Kostadinov J, Post KD, 
Geer EB. Predictors of mortality and long-term outcomes in treated 
Cushing’s disease: a study of 346 patients. J Clin Endocrinol Metab 
2013; 98: 1022–30.
28 Dekkers OM, Horváth-Puhó E, Jørgensen JO, et al. Multisystem 
morbidity and mortality in Cushing’s syndrome: a cohort study. 
J Clin Endocrinol Metab 2013; 98: 2277–84.
29 Graversen D, Vestergaard P, Stochholm K, Gravholt CH, 
Jørgensen JO. Mortality in Cushing’s syndrome: a systematic review 
and meta-analysis. Eur J Intern Med 2012; 23: 278–82.
30 Pivonello R, Faggiano A, Lombardi G, Colao A. The metabolic 
syndrome and cardiovascular risk in Cushing’s syndrome. 
Endocrinol Metab Clin North Am 2005; 34: 327–39, viii.
31 Wang M. The role of glucocorticoid action in the pathophysiology of 
the metabolic syndrome. Nutr Metab (Lond) 2005; 2: 3.
32 Pivonello R, De Leo M, Vitale P, et al. Pathophysiology of diabetes 
mellitus in Cushing’s syndrome. Neuroendocrinology 2010; 
92 (suppl 1): 77–81.
33 Lee MJ, Pramyothin P, Karastergiou K, Fried SK. Deconstructing the 
roles of glucocorticoids in adipose tissue biology and the development 
of central obesity. Biochim Biophys Acta 2014; 1842: 473–81.
34 Tataranni PA, Larson DE, Snitker S, Young JB, Flatt JP, Ravussin E. 
Eff ects of glucocorticoids on energy metabolism and food intake in 
humans. Am J Physiol 1996; 271: E317–25.
35 Galton DJ, Wilson JP. Lipogenesis in adipose tissue of patients with 
obesity and Cushing’s disease. Clin Sci 1972; 43: 17P.
36 Faggiano A, Pivonello R, Spiezia S, et al. Cardiovascular risk factors 
and common carotid artery caliber and stiff ness in patients with 
Cushing’s disease during active disease and 1 year after disease 
remission. J Clin Endocrinol Metab 2003; 88: 2527–33.
37 Mancini T, Kola B, Mantero F, Boscaro M, Arnaldi G. High 
cardiovascular risk in patients with Cushing’s syndrome according to 
1999 WHO/ISH guidelines. Clin Endocrinol (Oxf) 2004; 61: 768–77.
38 Giordano R, Picu A, Marinazzo E, et al. Metabolic and 
cardiovascular outcomes in patients with Cushing’s syndrome of 
diff erent aetiologies during active disease and 1 year after 
remission. Clin Endocrinol (Oxf) 2011; 75: 354–60.
39 Barahona MJ, Sucunza N, Resmini E, et al. Persistent body fat mass 
and infl ammatory marker increases after long-term cure of 
Cushing’s syndrome. J Clin Endocrinol Metab 2009; 94: 3365–71.
40 Colao A, Pivonello R, Spiezia S, et al. Persistence of increased 
cardiovascular risk in patients with Cushing’s disease after fi ve 
years of successful cure. J Clin Endocrinol Metab 1999; 84: 2664–72.
41 Geer EB, Shen W, Gallagher D, et al. MRI assessment of lean and 
adipose tissue distribution in female patients with Cushing’s 
disease. Clin Endocrinol (Oxf) 2010; 73: 469–75.
42 Albiger N, Testa RM, Almoto B, et al. Patients with Cushing’s 
syndrome have increased intimal media thickness at diff erent 
vascular levels: comparison with a population matched for similar 
cardiovascular risk factors. Horm Metab Res 2006; 38: 405–10.
43 Geer EB, Shen W, Strohmayer E, Post KD, Freda PU. Body 
composition and cardiovascular risk markers after remission of 
Cushing’s disease: a prospective study using whole-body MRI. 
J Clin Endocrinol Metab 2012; 97: 1702–11.
44 Giordano C, Guarnotta V, Pivonello R, et al. Is diabetes in Cushing’s 
syndrome only a consequence of hypercortisolism? Eur J Endocrinol 
2014; 170: 311–19.
45 Pecori Giraldi F, Moro M, Cavagnini F, and the Study Group on the 
Hypothalamo-Pituitary-Adrenal Axis of the Italian Society of 
Endocrinology. Gender-related diff erences in the presentation and 
course of Cushing’s disease. J Clin Endocrinol Metab 2003; 
88: 1554–58.
46 Pivonello R, De Martino MC, Cappabianca P, et al. The medical 
treatment of Cushing’s disease: eff ectiveness of chronic treatment 
with the dopamine agonist cabergoline in patients unsuccessfully 
treated by surgery. J Clin Endocrinol Metab 2009; 94: 223–30.
47 Castinetti F, Morange I, Jaquet P, Conte-Devolx B, Brue T. 
Ketoconazole revisited: a preoperative or postoperative treatment in 
Cushing’s disease. Eur J Endocrinol 2008; 158: 91–99.
48 Castinetti F, Guignat L, Giraud P, et al. Ketoconazole in Cushing’s 
disease: is it worth a try? J Clin Endocrinol Metab 2014; 99: 1623–30.
49 Moncet D, Morando DJ, Pitoia F, Katz SB, Rossi MA, Bruno OD. 
Ketoconazole therapy: an effi  cacious alternative to achieve 
eucortisolism in patients with Cushing’s syndrome. 
Medicina (B Aires) 2007; 67: 26–31.
50 Baudry C, Coste J, Bou Khalil R, et al. Effi  ciency and tolerance of 
mitotane in Cushing’s disease in 76 patients from a single center. 
Eur J Endocrinol 2012; 167: 473–81.
51 Fleseriu M, Biller BM, Findling JW, Molitch ME, Schteingart DE, 
Gross C, and the SEISMIC Study Investigators. Mifepristone, a 
glucocorticoid receptor antagonist, produces clinical and metabolic 
benefi ts in patients with Cushing’s syndrome. 
J Clin Endocrinol Metab 2012; 97: 2039–49.
52 Castinetti F, Fassnacht M, Johanssen S, et al. Merits and pitfalls of 
mifepristone in Cushing’s syndrome. Eur J Endocrinol 2009; 
160: 1003–10.
53 Katznelson L, Loriaux DL, Feldman D, Braunstein GD, Schteingart DE, 
Gross C. Global clinical response in Cushing’s syndrome patients 
treated with mifepristone. Clin Endocrinol (Oxf) 2014; 80: 562–69.
54 Wallia A, Colleran K, Purnell JQ, Gross C, Molitch ME. Improvement 
in insulin sensitivity during mifepristone treatment of Cushing 
syndrome: early and late eff ects. Diabetes Care 2013; 36: e147–48.
55 Pivonello R, Petersenn S, Newell-Price J, et al, and the Pasireotide 
B2305 Study Group. Pasireotide treatment signifi cantly improves 
clinical signs and symptoms in patients with Cushing’s disease: 
results from a phase III study. Clin Endocrinol (Oxf) 2014; 81: 408–17.
56 Valassi E, Santos A, Yaneva M, et al, and the ERCUSYN Study 
Group. The European Registry on Cushing’s syndrome: 2-year 
experience. Baseline demographic and clinical characteristics. 
Eur J Endocrinol 2011; 165: 383–92.
57 Pivonello R, De Martino MC, De Leo M, et al. Cushing’s syndrome: 
aftermath of the cure. Arq Bras Endocrinol Metabol 2007; 51: 1381–91.
58 Jeff coate WJ, Rees LH, Tomlin S, Jones AE, Edwards CR, 
Besser GM. Metyrapone in long-term management of Cushing’s 
disease. BMJ 1977; 2: 215–17.
59 Colao A, Petersenn S, Newell-Price J, et al, and the Pasireotide 
B2305 Study Group. A 12-month phase 3 study of pasireotide in 
Cushing’s disease. N Engl J Med 2012; 366: 914–24.
60 Henry RR, Ciaraldi TP, Armstrong D, Burke P, Ligueros-Saylan M, 
Mudaliar S. Hyperglycemia associated with pasireotide: results 
from a mechanistic study in healthy volunteers. J Clin Endocrinol 
Metab 2013; 98: 3446–53.
61 Colao A, De Block C, Gaztambide MS, Kumar S, Seufert J, 
Casanueva FF. Managing hyperglycemia in patients with Cushing’s 
disease treated with pasireotide: medical expert recommendations. 
Pituitary 2014; 17: 180–86.
62 Filipsson H, Monson JP, Koltowska-Häggström M, Mattsson A, 
Johannsson G. The impact of glucocorticoid replacement regimens 
on metabolic outcome and comorbidity in hypopituitary patients. 
J Clin Endocrinol Metab 2006; 91: 3954–61.
63 Munir A, Newell-Price J. Management of diabetes mellitus in 
Cushing’s syndrome. Neuroendocrinology 2010; 92 (suppl 1): 82–85.
64 Isidori AM, Graziadio C, Paragliola RM, et al, and the ABC Study 
Group. The hypertension of Cushing’s syndrome: controversies in 
the pathophysiology and focus on cardiovascular complications. 
J Hypertens 2015; 33: 44–60.
65 Gómez RM, Albiger NM, Díaz AG, Moncet D, Pitoia FA, Bruno OD. 
Eff ect of hypercortisolism control on high blood pressure in 
Cushing’s syndrome. Medicina (B Aires) 2007; 67: 439–44.
66 Isidori AM, Minnetti M, Sbardella E, Graziadio C, Grossman AB. 
Mechanisms in endocrinology: the spectrum of haemostatic 
abnormalities in glucocorticoid excess and defect. Eur J Endocrinol 
2015; 173: R101–13.
67 Pereira AM, Delgado V, Romijn JA, Smit JW, Bax JJ, Feelders RA. 
Cardiac dysfunction is reversed upon successful treatment of 
Cushing’s syndrome. Eur J Endocrinol 2010; 162: 331–40.
18 www.thelancet.com/diabetes-endocrinology   Published online May 10, 2016   http://dx.doi.org/10.1016/S2213-8587(16)00086-3
Review
68 Jyotsna VP, Naseer A, Sreenivas V, Gupta N, Deepak KK. Eff ect of 
Cushing’s syndrome—endogenous hypercortisolemia on 
cardiovascular autonomic functions. Auton Neurosci 2011; 
160: 99–102.
69 Torpy DJ, Mullen N, Ilias I, Nieman LK. Association of 
hypertension and hypokalemia with Cushing’s syndrome caused by 
ectopic ACTH secretion: a series of 58 cases. Ann N Y Acad Sci 
2002; 970: 134–44.
70 Muiesan ML, Lupia M, Salvetti M, et al. Left ventricular structural 
and functional characteristics in Cushing’s syndrome. 
J Am Coll Cardiol 2003; 41: 2275–79.
71 Pecori Giraldi F, Toja PM, De Martin M, et al. Circadian blood 
pressure profi le in patients with active Cushing’s disease and after 
long-term cure. Horm Metab Res 2007; 39: 908–14.
72 Storr HL, Isidori AM, Monson JP, Besser GM, Grossman AB, 
Savage MO. Prepubertal Cushing’s disease is more common in 
males, but there is no increase in severity at diagnosis. 
J Clin Endocrinol Metab 2004; 89: 3818–20.
73 Bertagna X, Pivonello R, Fleseriu M, et al. LCI699, a potent 
11β-hydroxylase inhibitor, normalizes urinary cortisol in patients 
with Cushing’s disease: results from a multicenter, proof-of-concept 
study. J Clin Endocrinol Metab 2014; 99: 1375–83.
74 Castinetti F, Brue T, Conte-Devolx B. The use of the glucocorticoid 
receptor antagonist mifepristone in Cushing’s syndrome. 
Curr Opin Endocrinol Diabetes Obes 2012; 19: 295–99.
75 Kamenický P, Redheuil A, Roux C, et al. Cardiac structure and 
function in Cushing’s syndrome: a cardiac magnetic resonance 
imaging study. J Clin Endocrinol Metab 2014; 99: E2144–53.
76 Ainscough JF, Drinkhill MJ, Sedo A, et al. Angiotensin II type-1 
receptor activation in the adult heart causes blood 
pressure-independent hypertrophy and cardiac dysfunction. 
Cardiovasc Res 2009; 81: 592–600.
77 Brilla CG, Weber KT. Mineralocorticoid excess, dietary sodium, and 
myocardial fi brosis. J Lab Clin Med 1992; 120: 893–901.
78 Pecori Giraldi F, Toja PM, Michailidis G, et al. High prevalence of 
prolonged QT interval duration in male patients with Cushing’s 
disease. Exp Clin Endocrinol Diabetes 2011; 119: 221–24.
79 Faggiano A, Melis D, Alfi eri R, et al. Sulfur amino acids in 
Cushing’s disease: insight in homocysteine and taurine levels in 
patients with active and cured disease. J Clin Endocrinol Metab 2005; 
90: 6616–22.
80 Yiu KH, Marsan NA, Delgado V, et al. Increased myocardial fi brosis 
and left ventricular dysfunction in Cushing’s syndrome. 
Eur J Endocrinol 2012; 166: 27–34.
81 van der Pas R, Leebeek FW, Hofl and LJ, de Herder WW, 
Feelders RA. Hypercoagulability in Cushing’s syndrome: 
prevalence, pathogenesis and treatment. Clin Endocrinol (Oxf) 
2013; 78: 481–88.
82 van der Pas R, de Bruin C, Leebeek FW, et al. The hypercoagulable 
state in Cushing’s disease is associated with increased levels of 
procoagulant factors and impaired fi brinolysis, but is not reversible 
after short-term biochemical remission induced by medical therapy. 
J Clin Endocrinol Metab 2012; 97: 1303–10.
83 Boscaro M, Sonino N, Scarda A, et al. Anticoagulant prophylaxis 
markedly reduces thromboembolic complications in Cushing’s 
syndrome. J Clin Endocrinol Metab 2002; 87: 3662–66.
84 Levis JT. ECG diagnosis: hypokalemia. Perm J 2012; 16: 57.
85 Arteaga E, Fardella C, Campusano C, Cárdenas I, Martinez P. 
Persistent hypokalemia after successful adrenalectomy in a patient 
with Cushing’s syndrome due to ectopic ACTH secretion: 
possible role of 11beta-hydroxysteroid dehydrogenase inhibition. 
J Endocrinol Invest 1999; 22: 857–59.
86 Fareau GG, Vassilopoulou-Sellin R. Hypercortisolemia and 
infection. Infect Dis Clin North Am 2007; 21: 639–57, viii.
87 Kovalovsky D, Refojo D, Holsboer F, Arzt E. Molecular mechanisms 
and Th1/Th2 pathways in corticosteroid regulation of cytokine 
production. J Neuroimmunol 2000; 109: 23–29.
88 Ilias I, Torpy DJ, Pacak K, Mullen N, Wesley RA, Nieman LK. 
Cushing’s syndrome due to ectopic corticotropin secretion: 
twenty years’ experience at the National Institutes of Health. 
J Clin Endocrinol Metab 2005; 90: 4955–62.
89 Sarlis NJ, Chanock SJ, Nieman LK. Cortisolemic indices predict 
severe infections in Cushing syndrome due to ectopic production of 
adrenocorticotropin. J Clin Endocrinol Metab 2000; 85: 42–47.
90 Ejaz S, Vassilopoulou-Sellin R, Busaidy NL, et al. Cushing syndrome 
secondary to ectopic adrenocorticotropic hormone secretion: 
the University of Texas MD Anderson Cancer Center Experience. 
Cancer 2011; 117: 4381–89.
91 Broder MS, Neary MP, Chang E, Ludlam WH. Incremental healthcare 
resource utilization and costs in US patients with Cushing’s disease 
compared with diabetes mellitus and population controls. Pituitary 
2015; 18: 796–802.
92 Bakker RC, Gallas PR, Romijn JA, Wiersinga WM. Cushing’s 
syndrome complicated by multiple opportunistic infections. 
J Endocrinol Invest 1998; 21: 329–33.
93 Lionakis MS, Kontoyiannis DP. Glucocorticoids and invasive fungal 
infections. Lancet 2003; 362: 1828–38.
94 Rizwan A, Sarfaraz A, Jabbar A, Akhter J, Islam N. Case report: 
nocardia infection associated with ectopic cushings. 
BMC Endocr Disord 2014; 14: 51.
95 Graham BS, Tucker WS Jr. Opportunistic infections in endogenous 
Cushing’s syndrome. Ann Intern Med 1984; 101: 334–38.
96 Razavi B, O’Toole J, Schilling M, Razavi M. Cryptococcal meningitis, 
an endocrine emergency? Lancet 2000; 355: 1426.
97 Oosterhuis JK, van den Berg G, Monteban-Kooistra WE, et al. 
Life-threatening Pneumocystis jiroveci pneumonia following treatment 
of severe Cushing’s syndrome. Neth J Med 2007; 65: 215–17.
98 Takasu N, Komiya I, Nagasawa Y, Asawa T, Yamada T. Exacerbation of 
autoimmune thyroid dysfunction after unilateral adrenalectomy in 
patients with Cushing’s syndrome due to an adrenocortical adenoma. 
N Engl J Med 1990; 322: 1708–12.
99 Takasu N, Ohara N, Yamada T, Komiya I. Development of 
autoimmune thyroid dysfunction after bilateral adrenalectomy in a 
patient with Carney’s complex and after removal of ACTH-producing 
pituitary adenoma in a patient with Cushing’s disease. 
J Endocrinol Invest 1993; 16: 697–702.
100 Colao A, Pivonello R, Faggiano A, et al. Increased prevalence of 
thyroid autoimmunity in patients successfully treated for Cushing’s 
disease. Clin Endocrinol (Oxf) 2000; 53: 13–19.
101 da Mota F, Murray C, Ezzat S. Overt immune dysfunction after 
Cushing’s syndrome remission: a consecutive case series and 
review of the literature. J Clin Endocrinol Metab 2011; 
96: E1670–74.
102 Neto MB, Machado MC, Mesquita F, et al. Thymus hyperplasia after 
resolution of hypercortisolism in ACTH-dependent Cushing’s 
syndrome: the importance of thymic vein catheterization. 
Eur J Endocrinol 2006; 154: 807–11.
103 Di Somma C, Pivonello R, Loche S, et al. Severe impairment of 
bone mass and turnover in Cushing’s disease: comparison between 
childhood-onset and adulthood-onset disease. Clin Endocrinol (Oxf) 
2002; 56: 153–58.
104 Di Somma C, Pivonello R, Loche S, et al. Eff ect of 2 years of cortisol 
normalization on the impaired bone mass and turnover in 
adolescent and adult patients with Cushing’s disease: a prospective 
study. Clin Endocrinol (Oxf) 2003; 58: 302–08.
105 Kawamata A, Iihara M, Okamoto T, Obara T. Bone mineral density 
before and after surgical cure of Cushing’s syndrome due to 
adrenocortical adenoma: prospective study. World J Surg 2008; 
32: 890–96.
106 Minetto M, Reimondo G, Osella G, Ventura M, Angeli A, 
Terzolo M. Bone loss is more severe in primary adrenal than in 
pituitary-dependent Cushing’s syndrome. Osteoporos Int 2004; 
15: 855–61.
107 Ohmori N, Nomura K, Ohmori K, Kato Y, Itoh T, Takano K. 
Osteoporosis is more prevalent in adrenal than in pituitary 
Cushing’s syndrome. Endocr J 2003; 50: 1–7.
108 Tauchmanovà L, Pivonello R, De Martino MC, et al. Eff ects of sex 
steroids on bone in women with subclinical or overt endogenous 
hypercortisolism. Eur J Endocrinol 2007; 157: 359–66.
109 van der Eerden AW, den Heijer M, Oyen WJ, Hermus AR. 
Cushing’s syndrome and bone mineral density: lowest Z scores in 
young patients. Neth J Med 2007; 65: 137–41.
110 dos Santos CV, Vieira Neto L, Madeira M, et al. Bone density and 
microarchitecture in endogenous hypercortisolism. 
Clin Endocrinol (Oxf) 2015; 83: 468–74.
111 Hermus AR, Smals AG, Swinkels LM, et al. Bone mineral density 
and bone turnover before and after surgical cure of Cushing’s 
syndrome. J Clin Endocrinol Metab 1995; 80: 2859–65.
www.thelancet.com/diabetes-endocrinology   Published online May 10, 2016   http://dx.doi.org/10.1016/S2213-8587(16)00086-3 19
Review
112 Randazzo ME, Grossrubatscher E, Dalino Ciaramella P, Vanzulli A, 
Loli P. Spontaneous recovery of bone mass after cure of 
endogenous hypercortisolism. Pituitary 2012; 15: 193–201.
113 Tauchmanovà L, Pivonello R, Di Somma C, et al. 
Bone demineralization and vertebral fractures in endogenous 
cortisol excess: role of disease etiology and gonadal status. 
J Clin Endocrinol Metab 2006; 91: 1779–84.
114 Trementino L, Appolloni G, Ceccoli L, et al. Bone complications in 
patients with Cushing’s syndrome: looking for clinical, biochemical, 
and genetic determinants. Osteoporos Int 2014; 25: 913–21.
115 Barahona MJ, Sucunza N, Resmini E, et al. Deleterious eff ects of 
glucocorticoid replacement on bone in women after long-term 
remission of Cushing’s syndrome. J Bone Miner Res 2009; 
24: 1841–46.
116 Di Somma C, Colao A, Pivonello R, et al. Eff ectiveness of chronic 
treatment with alendronate in the osteoporosis of Cushing’s 
disease. Clin Endocrinol (Oxf) 1998; 48: 655–62.
117 Chiodini I, Carnevale V, Torlontano M, et al. Alterations of bone 
turnover and bone mass at diff erent skeletal sites due to pure 
glucocorticoid excess: study in eumenorrheic patients with 
Cushing’s syndrome. J Clin Endocrinol Metab 1998; 83: 1863–67.
118 Kristo C, Jemtland R, Ueland T, Godang K, Bollerslev J. Restoration 
of the coupling process and normalization of bone mass following 
successful treatment of endogenous Cushing’s syndrome: 
a prospective, long-term study. Eur J Endocrinol 2006; 154: 109–18.
119 Vestergaard P, Lindholm J, Jørgensen JO, et al. Increased risk of 
osteoporotic fractures in patients with Cushing’s syndrome. 
Eur J Endocrinol 2002; 146: 51–56.
120 Füto L, Toke J, Patócs A, et al. Skeletal diff erences in bone mineral 
area and content before and after cure of endogenous Cushing’s 
syndrome. Osteoporos Int 2008; 19: 941–49.
121 Canalis E, Mazziotti G, Giustina A, Bilezikian JP. 
Glucocorticoid-induced osteoporosis: pathophysiology and 
therapy. Osteoporos Int 2007; 18: 1319–28.
122 Weinstein RS. Clinical practice. Glucocorticoid-induced bone 
disease. N Engl J Med 2011; 365: 62–70.
123 Seibel MJ, Cooper MS, Zhou H. Glucocorticoid-induced 
osteoporosis: mechanisms, management, and future perspectives. 
Lancet Diabetes Endocrinol 2013; 1: 59–70.
124 Luisetto G, Zangari M, Camozzi V, Boscaro M, Sonino N, Fallo F. 
Recovery of bone mineral density after surgical cure, but not by 
ketoconazole treatment, in Cushing’s syndrome. Osteoporos Int 
2001; 12: 956–60.
125 Scillitani A, Mazziotti G, Di Somma C, et al, and the ABC Group. 
Treatment of skeletal impairment in patients with endogenous 
hypercortisolism: when and how? Osteoporos Int 2014; 25: 441–46.
126 Minetto MA, Lanfranco F, Motta G, Allasia S, Arvat E, D’Antona G. 
Steroid myopathy: some unresolved issues. J Endocrinol Invest 2011; 
34: 370–75.
127 Schakman O, Kalista S, Barbé C, Loumaye A, Thissen JP. 
Glucocorticoid-induced skeletal muscle atrophy. Int J Biochem 
Cell Biol 2013; 45: 2163–72.
128 Aulinas A, Colom C, Ybarra J, et al. Immediate and delayed 
postoperative morbidity in functional and non-functioning pituitary 
adenomas. Pituitary 2012; 15: 380–85.
129 Pivonello R, Simeoli C, De Martino MC, et al. Neuropsychiatric 
disorders in Cushing’s syndrome. Front Neurosci 2015; 9: 129.
130 Sonino N, Fava GA. Psychiatric disorders associated with Cushing’s 
syndrome. Epidemiology, pathophysiology and treatment. 
CNS Drugs 2001; 15: 361–73.
131 De Kloet ER, Vreugdenhil E, Oitzl MS, Joëls M. Brain corticosteroid 
receptor balance in health and disease. Endocr Rev 1998; 
19: 269–301.
132 Jacobs BL, van Praag H, Gage FH. Adult brain neurogenesis and 
psychiatry: a novel theory of depression. Mol Psychiatry 2000; 
5: 262–69.
133 Patil CG, Lad SP, Katznelson L, Laws ER Jr. Brain atrophy and 
cognitive defi cits in Cushing’s disease. Neurosurg Focus 2007; 
23: E11.
134 Bleicken B, Hahner S, Loeffl  er M, et al. Infl uence of hydrocortisone 
dosage scheme on health-related quality of life in patients with 
adrenal insuffi  ciency. Clin Endocrinol (Oxf) 2010; 72: 297–304.
135 Kaltsas GA, Korbonits M, Isidori AM, et al. How common are 
polycystic ovaries and the polycystic ovarian syndrome in women 
with Cushing’s syndrome? Clin Endocrinol (Oxf) 2000; 53: 493–500.
136 Lado-Abeal J, Rodriguez-Arnao J, Newell-Price JD, et al. 
Menstrual abnormalities in women with Cushing’s disease are 
correlated with hypercortisolemia rather than raised circulating 
androgen levels. J Clin Endocrinol Metab 1998; 83: 3083–88.
137 Gabrilove JL, Nicolis GL, Sohval AR. The testis in Cushing’s 
syndrome. J Urol 1974; 112: 95–99.
138 McKenna TJ, Lorber D, Lacroix A, Rabin D. Testicular activity in 
Cushing’s disease. Acta Endocrinol (Copenh) 1979; 91: 501–10.
139 Pivonello R, De Martino MC, Auriemma RS, et al. Pituitary tumors 
and pregnancy: the interplay between a pathologic condition and a 
physiologic status. J Endocrinol Invest 2014; 37: 99–112.
140 Whirledge S, Cidlowski JA. Glucocorticoids, stress, and fertility. 
Minerva Endocrinol 2010; 35: 109–25.
141 Unuane D, Tournaye H, Velkeniers B, Poppe K. Endocrine 
disorders & female infertility. Best Pract Res Clin Endocrinol Metab 
2011; 25: 861–73.
142 Brzana J, Yedinak CG, Hameed N, Plesiu A, McCartney S, 
Fleseriu M. Polycystic ovarian syndrome and Cushing’s syndrome: 
a persistent diagnostic quandary. Eur J Obstet Gynecol Reprod Biol 
2014; 175: 145–48.
143 Putignano P, Bertolini M, Losa M, Cavagnini F. Screening for 
Cushing’s syndrome in obese women with and without polycystic 
ovary syndrome. J Endocrinol Invest 2003; 26: 539–44.
144 Pall ME, Lao MC, Patel SS, et al. Testosterone and bioavailable 
testosterone help to distinguish between mild Cushing’s syndrome 
and polycystic ovarian syndrome. Horm Metab Res 2008; 40: 813–18.
145 Carmina E, Rosato F, Jannì A, Rizzo M, Longo RA. Extensive clinical 
experience: relative prevalence of diff erent androgen excess 
disorders in 950 women referred because of clinical 
hyperandrogenism. J Clin Endocrinol Metab 2006; 91: 2–6.
146 Iannaccone A, Gabrilove JL, Sohval AR, Soff er LJ. The ovaries in 
Cushing’s syndrome. N Engl J Med 1959; 261: 775–80.
147 Kaltsas GA, Isidori AM, Kola BP, et al. The value of the low-dose 
dexamethasone suppression test in the diff erential diagnosis of 
hyperandrogenism in women. J Clin Endocrinol Metab 2003; 
88: 2634–43.
148 Ferraù F, Losa M, Cotta OR, et al. Course of pregnancies in women 
with Cushing’s disease treated by gamma-knife. Gynecol Endocrinol 
2012; 28: 827–29.
149 Lindsay JR, Jonklaas J, Oldfi eld EH, Nieman LK. Cushing’s syndrome 
during pregnancy: personal experience and review of the literature. 
J Clin Endocrinol Metab 2005; 90: 3077–83.
150 Bronstein MD, Machado MC, Fragoso MC. Management of 
endocrine disease: management of pregnant patients with 
Cushing’s syndrome. Eur J Endocrinol 2015; 173: R85–91.
151 Luton JP, Thieblot P, Valcke JC, Mahoudeau JA, Bricaire H. 
Reversible gonadotropin defi ciency in male Cushing’s disease. 
J Clin Endocrinol Metab 1977; 45: 488–95.
152 Pozza C, Graziadio C, Giannetta E, Lenzi A, Isidori AM. 
Management strategies for aggressive Cushing’s syndrome: 
from macroadenomas to ectopics. J Oncol 2012; 2012: 685213.
153 Davidovici BB, Orion E, Wolf R. Cutaneous manifestations of 
pituitary gland diseases. Clin Dermatol 2008; 26: 288–95.
154 Stratakis CA, Mastorakos G, Mitsiades NS, Mitsiades CS, 
Chrousos GP. Skin manifestations of Cushing disease in children 
and adolescents before and after the resolution of 
hypercortisolemia. Pediatr Dermatol 1998; 15: 253–58.
